≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Aspergillosis

EFO Endpoint Browser PheWeb

AB1_ASPERGILLOSIS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — B44
  • Hospital discharge: ICD-9 — 1173
  • Hospital discharge: ICD-8 — 1173
  • Cause of death: ICD-10 — B44
  • Cause of death: ICD-9 — 1173
  • Cause of death: ICD-8 — 1173

2 out of 7 registries used, show all original rules.

327

4. Check minimum number of events

None

327

5. Include endpoints

None

327

6. Filter based on genotype QC (FinnGen only)

312

Control definitions (FinnGen only)

Control exclude
AB1_MYCOSES

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF5

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1897 694 1166
Only index persons 1320 508 812
Unadjusted period prevalence (%)
Whole population 0.03 0.02 0.03
Only index persons 0.03 0.02 0.03
Median age at first event (years)
Whole population 62.18 61.22 62.71
Only index persons 62.61 60.94 63.65

-FinnGen-

Key figures

All Female Male
Number of individuals 312 120 192
Unadjusted period prevalence (%) 0.07 0.04 0.09
Median age at first event (years) 64.10 59.62 66.90

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
327
Matched controls
3270
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
B44.1
ICD-10 Finland
Other pulmonary aspergillosis
+∞
167.5
146
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
18.3
146.8
148
141
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
20.2
137.8
124
96
J02AC03
ATC
voriconazole; systemic
407.5
134.0
126
5
TGC00
NOMESCO Finland
Bronchial lavation
24.8
128.6
100
57
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
11.3
102.2
144
213
J01MA14
ATC
moxifloxacin; systemic
10.4
87.9
125
184
R03BB04
ATC
tiotropium bromide; inhalant
9.3
81.0
128
212
B44.0
ICD-10 Finland
Invasive pulmonary aspergillosis
+∞
80.6
74
*
GD1AD
NOMESCO Finland
Thorax CT examination
11.3
80.2
100
123
J18.9
ICD-10 Finland
Pneumonia, unspecified
8.2
80.0
216
626
J47
ICD-10 Finland
Bronchiectasis
23.3
76.4
58
30
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
11.2
69.5
84
98
R04.2
ICD-10 Finland
Haemoptysis
16.8
69.2
62
45
B44.9
ICD-10 Finland
Aspergillosis, unspecified
+∞
67.0
62
*
B44.8
ICD-10 Finland
Other forms of aspergillosis
773.7
66.4
63
*
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
8.4
64.5
103
169
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
15.4
64.0
60
47
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
14.0
64.0
64
56
127
Kela drug reimbursment
Transplant complication
31.1
61.1
41
15
J45.0
ICD-10 Finland
Predominantly allergic asthma
7.7
52.6
88
150
J01MA12
ATC
levofloxacin; systemic
5.7
52.5
150
426
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
5.4
49.2
144
414
GD1AA
NOMESCO Finland
Thorax X-ray examination
6.2
45.2
260
1262
H62.2*B44.8
ICD-10 Finland
Otitis externa in aspergillosis
+∞
43.7
41
*
H02AB06
ATC
prednisolone; systemic
5.4
42.5
247
1185
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.9
40.7
127
377
R03AK08
ATC
formoterol and beclometasone; inhalant
9.2
40.4
53
67
J45.9
ICD-10 Finland
Asthma, unspecified
4.8
40.3
128
385
J45.1
ICD-10 Finland
Nonallergic asthma
6.9
40.3
71
126
R03DC03
ATC
montelukast; oral
5.1
39.3
108
288
R03AK06
ATC
salmeterol and fluticasone; inhalant
4.9
38.8
113
316
XG410
NOMESCO Finland
Flow-volume spirometry
8.6
36.7
51
69
L03AA02
ATC
filgrastim; parenteral
10.0
36.3
44
50
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
7.4
35.5
57
91
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
8.4
35.4
50
69
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.9
34.4
59
101
H02AB04
ATC
methylprednisolone; systemic
4.6
33.7
102
291
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
6.4
33.6
63
118
R81
ICPC
Pneumonia
8.6
32.2
44
58
R03AC12
ATC
salmeterol; inhalant
7.1
31.6
52
85
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.9
30.2
79
199
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.3
30.0
56
104
R50.9
ICD-10 Finland
Fever, unspecified
4.2
28.9
100
312
XW000
NOMESCO Finland
Bone marrow biopsy
7.1
28.7
47
76
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
9.4
28.0
35
41
J46
ICD-10 Finland
Status asthmaticus
12.1
27.9
29
26
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
3.8
27.7
231
1270
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
5.3
27.2
62
138
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
4.5
27.2
80
220
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.2
26.4
87
260
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
6.1
26.3
50
94
H02AB07
ATC
prednisone; oral
4.2
26.2
84
246
J02AC05
ATC
isavuconazole; systemic
269.8
25.0
25
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.0
24.8
85
261
R03DA04
ATC
theophylline; systemic, rectal
5.6
24.1
50
102
R03AC13
ATC
formoterol; inhalant
6.1
23.6
44
81
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
8.3
23.4
32
42
R03BA01
ATC
beclometasone; inhalant
4.0
23.1
79
241
J02AC04
ATC
posaconazole; systemic
246.6
22.9
23
*
WW500
NOMESCO Finland
Blood transfusion
6.5
22.9
40
69
R03BA05
ATC
fluticasone; inhalant
3.5
22.3
98
354
J45.8
ICD-10 Finland
Mixed asthma
8.5
21.6
29
37
H02AB09
ATC
hydrocortisone; systemic
8.2
21.6
30
40
A31.0
ICD-10 Finland
Pulmonary mycobacterial infection
82.3
21.0
23
*
WW200
NOMESCO Finland
Immunization
9.3
20.9
26
30
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
7.3
20.3
31
46
R03AL01
ATC
fenoterol and ipratropium bromide; inhalant
6.8
20.1
33
53
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.9
20.1
154
761
J17.2*B44.1
ICD-10 Finland
Pneumonia in other aspergillosis
+∞
20.0
19
*
JN4BD
NOMESCO Finland
Extensive body CT
3.9
20.0
70
216
J09
ICD-10 Finland
Influenza due to identified zoonotic or pandemic influenza virus
8.1
19.4
27
36
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
4.6
19.4
51
127
WX892
NOMESCO Finland
Monitored bed care
4.6
19.4
51
127
R03AL09
ATC
formoterol, glycopyrronium bromide and beclometasone; inhalant
5.9
19.0
36
67
GDC00
NOMESCO Finland
Lobectomy of lung
74.4
18.9
21
*
J17.2*B44.0
ICD-10 Finland
Pneumonia in invasive aspergillosis
+∞
18.9
18
*
J44.0
ICD-10 Finland
Chronic obstructive pulmonary disease with acute lower respiratory infection
5.1
18.8
43
95
J01FA06
ATC
roxithromycin; oral
2.8
18.8
174
942
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
5.3
18.3
39
81
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
28.6
18.1
24
9
A07AA02
ATC
nystatin; oral
5.3
17.8
38
79
UDH02
NOMESCO Finland
Rhinopharyngoscopy
4.3
17.6
50
132
TDM10
NOMESCO Finland
Puncture of maxillary antrum
6.0
17.3
32
58
L04AA06
ATC
mycophenolic acid; systemic
14.3
17.3
29
22
R03AC02
ATC
salbutamol; inhalant
2.8
17.2
217
1354
WX302
NOMESCO Finland
Thoracal epidural anesthesy
5.6
17.1
34
66
L04AD02
ATC
tacrolimus; systemic
23.4
17.1
24
11
J22
ICD-10 Finland
Unspecified acute lower respiratory infection
4.3
17.0
48
126
49300
ICD-8 Finland
Asthma, bronchiale
7.2
16.8
26
39
R03AK11
ATC
formoterol and fluticasone; inhalant
7.2
16.8
26
39
A04AA01
ATC
ondansetron; systemic, rectal
4.0
16.8
52
146
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
3.0
16.6
98
413
J01FF01
ATC
clindamycin; systemic
2.8
16.5
121
573
J45
ICD-10 Finland
Asthma
3.8
16.5
57
173
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
13.8
16.5
28
22
WX408
NOMESCO Finland
General anesthesy, balanced
2.8
16.2
116
541
TPH04
NOMESCO Finland
Cathetrisation of vein
2.8
16.0
110
502
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
7.3
15.9
24
35
J01FA09
ATC
clarithromycin; systemic
2.6
15.4
129
649
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
6.7
15.2
25
40
TPX10
NOMESCO Finland
Implantation of vascular injection port
6.3
15.0
26
44
JN4CD
NOMESCO Finland
Very extensive body CT
5.7
14.9
29
55
Z2446
NOMESCO Finland
Social worker
4.4
14.8
40
101
JN4AD
NOMESCO Finland
Body CT examination
3.2
14.6
69
255
R03AK07
ATC
formoterol and budesonide; inhalant
2.8
14.5
93
407
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
6.6
14.4
24
39
ZX120
NOMESCO Finland
Intravenous
3.4
14.4
57
189
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.8
14.3
94
417
J96.1
ICD-10 Finland
Chronic respiratory failure
7.1
14.2
22
33
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.7
14.1
98
446
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
25.1
13.9
19
8
J01FA15
ATC
telithromycin; oral
3.5
13.9
53
171
L04AD01
ATC
ciclosporin; systemic
12.9
13.8
24
20
J01FA10
ATC
azithromycin; systemic
2.5
13.8
205
1324
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
19.3
13.5
20
11
J02AC02
ATC
itraconazole; systemic
2.9
13.5
77
316
J01AA02
ATC
doxycycline; systemic
3.2
13.1
279
2115
S81.8
ICD-10 Finland
Open wound of other parts of lower leg
6.5
13.1
22
36
R03BA08
ATC
ciclesonide; inhalant
3.6
12.9
47
147
A02BC02
ATC
pantoprazole; systemic
2.7
12.8
254
1844
J44.9
ICD-10 Finland
Chronic obstructive pulmonary disease, unspecified
4.3
12.8
35
89
XG474
NOMESCO Finland
Exhalation nntrogen oxide
6.0
12.6
23
41
J01GB01
ATC
tobramycin; inhalant, parenteral
135.0
12.5
13
*
J01MA02
ATC
ciprofloxacin; systemic
2.3
12.4
161
965
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.4
12.3
124
666
R03AL02
ATC
salbutamol and ipratropium bromide; inhalant
16.7
12.3
19
12
R03BA02
ATC
budesonide; inhalant
2.6
12.1
84
379
R03AK03
ATC
[U] fenoterol and ipratropium bromide
3.9
12.1
38
107
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.6
12.1
85
386
TPH07
NOMESCO Finland
Cathetrisation of artery
3.0
12.1
60
227
ZXD05
NOMESCO Finland
Urgent procedure
2.4
11.8
118
630
R06.0
ICD-10 Finland
Dyspnoea
2.4
11.8
119
638
J17.3*B59
ICD-10 Finland
Pneumonia due to Pneumocystis carinii
67.4
11.7
13
*
A05AA02
ATC
ursodeoxycholic acid; oral
10.6
11.2
21
21
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
5.7
11.0
21
39
Z94.2
ICD-10 Finland
Lung transplant status
44.9
11.0
13
*
M05BA04
ATC
alendronic acid; oral
3.5
11.0
41
130
XF400
NOMESCO Finland
ECG with 12 standard connections
2.6
10.9
75
336
H60.9
ICD-10 Finland
Otitis externa, unspecified
3.3
10.9
44
147
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
4.5
10.8
27
64
ZX112
NOMESCO Finland
Subcutaneous
5.5
10.7
21
40
J02AC01
ATC
fluconazole; systemic
2.2
10.7
127
724
J85.1
ICD-10 Finland
Abscess of lung with pneumonia
113.5
10.5
11
*
J05AB11
ATC
valaciclovir; oral
2.6
10.5
69
302
B44.7
ICD-10 Finland
Disseminated aspergillosis
+∞
10.5
10
*
C03CA01
ATC
furosemide; systemic
2.2
10.4
130
754
SPAT1255
SPAT
Intravenous administration of medicine
3.7
10.3
34
99
R4110
NOMESCO Finland
Physiotherapy
2.2
10.2
113
625
R03AC03
ATC
terbutaline; inhalant
2.8
10.1
58
236
ZX108
NOMESCO Finland
Inhalation
15.2
10.1
16
11
Z01.8
ICD-10 Finland
Other specified special examinations
2.3
10.1
92
468
R4190
NOMESCO Finland
Nutritional therapy
4.6
10.0
24
55
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
3.4
9.9
37
117
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
3.7
9.9
33
97
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.5
9.8
72
331
L03AA13
ATC
pegfilgrastim; parenteral
4.1
9.6
27
70
B02AA02
ATC
tranexamic acid; systemic
2.8
9.5
53
213
GDB10
NOMESCO Finland
Wedge resection of lung
+∞
9.4
9
*
R03BB01
ATC
ipratropium bromide; inhalant
4.1
9.3
26
67
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
14.2
9.3
15
11
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
5.2
9.2
19
38
R03AK04
ATC
salbutamol and sodium cromoglicate; inhalant
11.9
9.2
16
14
J44.1
ICD-10 Finland
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
4.3
9.1
24
59
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
4.4
9.1
23
55
Z3226
NOMESCO Finland
Physiotherapist
2.4
9.1
75
364
GDB11
NOMESCO Finland
Thoracoscopic wedge resection of lung
19.3
9.0
13
7
GD1CD
NOMESCO Finland
Thorax extensive CT-examination
13.0
9.0
15
12
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
2.1
8.8
105
591
GX1L5
NOMESCO Finland
Exhaled nitric oxide analysis
14.6
8.8
14
10
GA4YT
NOMESCO Finland
Puncture of pleura with ultrasound guidance
4.6
8.7
21
48
GDG10
NOMESCO Finland
Bilateral transplantation of lung
51.4
8.7
10
*
J85.2
ICD-10 Finland
Abscess of lung without pneumonia
51.4
8.7
10
*
J40
ICD-10 Finland
Bronchitis, not specified as acute or chronic
5.0
8.7
19
40
UDM02
NOMESCO Finland
Sinoscopy
6.7
8.6
21
33
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
16.8
8.6
13
8
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
28.4
8.5
11
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.2
8.5
82
424
GD1BT
NOMESCO Finland
Biopsy of lung with X-ray guidance
92.3
8.5
9
*
A03FA01
ATC
metoclopramide; systemic, rectal
2.2
8.4
85
447
J82
ICD-10 Finland
Pulmonary eosinophilia, not elsewhere classified
+∞
8.4
8
*
R01AD09
ATC
mometasone; nasal
2.0
8.4
155
1022
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.8
8.3
45
177
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.8
8.3
45
177
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
3.4
8.3
31
98
WX872
NOMESCO Finland
Intensive care
3.5
8.3
30
93
J01DB01
ATC
cefalexin; oral
2.5
8.3
280
2295
9823/3-C42.1
ICD-O-3
B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma of bone marrow
15.0
8.3
13
9
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
3.1
8.3
35
120
H72.0
ICD-10 Finland
Central perforation of tympanic membrane
7.1
8.2
19
28
RS220, ,
NOMESCO Finland
17.7
8.1
12
7
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
34.3
8.1
10
*
N02AA05
ATC
oxycodone; systemic
2.2
8.1
81
424
J98.1
ICD-10 Finland
Pulmonary collapse
22.7
8.1
11
5
ZXE40
NOMESCO Finland
More than seven and less than nine hours
6.9
8.0
19
29
Z2221
NOMESCO Finland
Medical doctor
2.1
8.0
98
556
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
4.0
7.9
23
61
H60.8
ICD-10 Finland
Other otitis externa
4.2
7.9
21
52
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.5
7.9
52
226
R01AD08
ATC
fluticasone; nasal
2.1
7.9
102
590
A41.9
ICD-10 Finland
Sepsis, unspecified
4.1
7.8
22
57
M04AA01
ATC
allopurinol; systemic
2.4
7.8
62
294
H66.0
ICD-10 Finland
Acute suppurative otitis media
3.3
7.8
31
102
J01CA04
ATC
amoxicillin; systemic
2.3
7.8
272
2220
L01BB05
ATC
fludarabine; systemic
46.1
7.7
9
*
5BA08, ,
NOMESCO Finland
46.1
7.7
9
*
R03AK10
ATC
vilanterol and fluticasone furoate; inhalant
3.6
7.7
26
77
R06.2
ICD-10 Finland
Wheezing
4.0
7.7
22
58
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
18.9
7.6
11
6
XGX32
NOMESCO Finland
Bronchoscopic ultrasonography
12.2
7.6
13
11
XG499
NOMESCO Finland
Other fysiological examination of respiatory function
25.7
7.6
10
*
XX2RW, ,
NOMESCO Finland
10.4
7.6
14
14
R03DC01
ATC
zafirlukast; oral
7.4
7.6
17
24
N02AX02
ATC
tramadol; systemic, rectal
1.9
7.5
158
1078
N03AX16
ATC
[U] pregabalin
2.1
7.4
87
483
A02BC01
ATC
omeprazole; systemic
2.0
7.4
98
570
J33.0
ICD-10 Finland
Polyp of nasal cavity
4.3
7.4
19
46
R06AE07
ATC
cetirizine; oral
1.9
7.4
139
912
A10AC01
ATC
insulin (human); parenteral
2.9
7.4
37
140
J93.1
ICD-10 Finland
Other spontaneous pneumothorax
20.6
7.2
10
5
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
9.1
7.1
14
16
J43.9
ICD-10 Finland
Emphysema, unspecified
6.1
7.0
18
31
GD5AD
NOMESCO Finland
Thorax and upper abdomen combined CT examination of
7.8
7.0
15
20
AA1AD
NOMESCO Finland
CT of head and brain
1.9
7.0
111
686
WX600
NOMESCO Finland
Single shot through catheter
14.2
6.9
11
8
J32.4
ICD-10 Finland
Chronic pansinusitis
8.5
6.9
14
17
JN6DR
NOMESCO Finland
PET-CT of whole body metabolism
9.6
6.8
13
14
ZXE30
NOMESCO Finland
More than five and less than seven hours
3.6
6.8
23
68
UGC18
NOMESCO Finland
Flexible bronchoscopy with biopsy of lung
17.1
6.8
10
6
Z94.0
ICD-10 Finland
Kidney transplant status
17.1
6.8
10
6
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
6.7
6.7
16
25
Y84.8
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
12.6
6.6
11
9
GAA10
NOMESCO Finland
Intercostal insertion of pleural drainage tube
7.1
6.6
15
22
J96.0
ICD-10 Finland
Acute respiratory failure
10.3
6.6
12
12
M05BA07
ATC
risedronic acid; oral
5.5
6.6
18
34
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
3.1
6.6
27
91
DCA20
NOMESCO Finland
Insertion of ventilating tube through tympanic membrane
6.4
6.6
16
26
B03XA02
ATC
darbepoetin alfa; parenteral
6.4
6.6
16
26
A10AB05
ATC
insulin aspart; parenteral
2.7
6.5
36
143
H60
ICD-10 Finland
Otitis externa
3.2
6.5
26
86
J10.0
ICD-10 Finland
Influenza with pneumonia, seasonal influenza virus identified
7.6
6.5
14
19
E000003, ,
ATC
3.6
6.4
21
61
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
8.4
6.4
13
16
R02
ICPC
Shortness of breath/dyspnoea
2.3
6.4
53
256
WX002
NOMESCO Finland
Sedation and analgesia
2.1
6.3
73
401
1XC02, ,
NOMESCO Finland
18.4
6.3
9
5
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
18.4
6.3
9
5
D72.1
ICD-10 Finland
Eosinophilia
18.4
6.3
9
5
A15.0
ICD-10 Finland
Tuberculosis of lung, confirmed by sputum microscopy with or without culture
+∞
6.3
6
*
2AA01, ,
NOMESCO Finland
+∞
6.3
6
*
J17.2
ICD-10 Finland
Pneumonia in mycoses
+∞
6.3
6
*
H60.3
ICD-10 Finland
Other infective otitis externa
4.1
6.2
17
43
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
3.3
6.1
23
73
J30.10
ICD-10 Finland
Allergic rhinitis due to pollen
3.7
6.1
19
53
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.0
6.1
27
95
J01DA01
ATC
[U] cefalexin
1.8
6.1
202
1547
ZXE00
NOMESCO Finland
One hour or less
1.8
6.1
128
858
H66.9
ICD-10 Finland
Otitis media, unspecified
3.1
6.0
26
90
A03
ICPC
Fever
2.1
6.0
61
319

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Pulmonary Disease
29 [38004472]
2.1e+00
3.0e+00
3.5e+00
—
3.7e+00
3.4e+00
3.1e+00
cases:48.93%
controls:10.94%
cases:55.35%
controls:5.85%
cases:29.36%
controls:1.26%
—
—
cases:33.87%
controls:1.29%
cases:62.09%
controls:5.20%
cases:72.68%
controls:10.89%
160
357
167
2906
181
191
146
3072
96
41
231
3222
—
105
42
205
3214
172
163
105
2969
141
266
53
2177
Hematology
82 [38004501]
2.3e+00
3.1e+00
4.0e+00
1.0e+50
3.8e+00
2.9e+00
2.1e+00
cases:9.79%
controls:1.07%
cases:14.07%
controls:0.74%
cases:10.40%
controls:0.21%
cases:9.17%
controls:0.00%
cases:9.68%
controls:0.25%
cases:11.19%
controls:0.70%
cases:12.37%
controls:1.68%
32
35
295
3228
46
24
281
3239
34
7
293
3256
30
0
297
3263
30
8
280
3248
31
22
246
3110
24
41
170
2402
FEV1/FVC
19926-5 [3011505]
1.9e+00
2.7e+00
3.3e+00
1.0e+50
2.7e+00
3.2e+00
3.2e+00
cases:14.68%
controls:2.54%
cases:11.31%
controls:0.86%
cases:3.98%
controls:0.15%
cases:2.45%
controls:0.00%
cases:2.26%
controls:0.15%
cases:14.08%
controls:0.64%
cases:27.84%
controls:1.56%
48
83
279
3180
37
28
290
3235
13
5
314
3258
8
0
319
3263
7
5
303
3251
39
20
238
3112
54
38
140
2405
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
1.9e+00
2.7e+00
3.3e+00
1.0e+50
2.7e+00
3.2e+00
3.2e+00
cases:14.68%
controls:2.54%
cases:11.31%
controls:0.86%
cases:3.98%
controls:0.15%
cases:2.45%
controls:0.00%
cases:2.26%
controls:0.15%
cases:14.08%
controls:0.64%
cases:27.84%
controls:1.56%
48
83
279
3180
37
28
290
3235
13
5
314
3258
8
0
319
3263
7
5
303
3251
39
20
238
3112
54
38
140
2405
FEV1
20150-9 [3024653]
1.9e+00
2.7e+00
3.3e+00
1.0e+50
2.7e+00
3.2e+00
3.2e+00
cases:14.68%
controls:2.54%
cases:11.31%
controls:0.86%
cases:3.98%
controls:0.15%
cases:2.45%
controls:0.00%
cases:2.26%
controls:0.15%
cases:14.08%
controls:0.64%
cases:27.84%
controls:1.56%
48
83
279
3180
37
28
290
3235
13
5
314
3258
8
0
319
3263
7
5
303
3251
39
20
238
3112
54
38
140
2405
Thorax X-ray examination
GD1AA [2001303617]
1.6e+00
2.7e+00
3.4e+00
1.0e+50
3.8e+00
2.9e+00
2.5e+00
cases:34.25%
controls:9.78%
cases:33.94%
controls:3.22%
cases:15.29%
controls:0.58%
cases:18.35%
controls:0.00%
cases:11.61%
controls:0.31%
cases:38.63%
controls:3.26%
cases:58.25%
controls:10.48%
112
319
215
2944
111
105
216
3158
50
19
277
3244
60
0
267
3263
36
10
274
3246
107
102
170
3030
113
256
81
2187
Outpatient Visit
OP [9202]
9.5e-01
1.7e+00
2.1e+00
5.1e+00
1.9e+00
1.8e+00
2.1e+00
cases:88.69%
controls:75.21%
cases:85.63%
controls:53.17%
cases:46.79%
controls:9.35%
cases:39.45%
controls:0.40%
cases:40.97%
controls:9.55%
cases:85.92%
controls:50.51%
cases:96.91%
controls:79.82%
290
2454
37
809
280
1735
47
1528
153
305
174
2958
129
13
198
3250
127
311
183
2945
238
1582
39
1550
188
1950
6
493
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
1.2e+00
2.2e+00
3.3e+00
1.0e+50
3.8e+00
2.7e+00
2.0e+00
cases:11.62%
controls:3.98%
cases:11.01%
controls:1.38%
cases:7.95%
controls:0.31%
cases:1.53%
controls:0.00%
cases:13.87%
controls:0.37%
cases:16.97%
controls:1.31%
cases:20.10%
controls:3.44%
38
130
289
3133
36
45
291
3218
26
10
301
3253
5
0
322
3263
43
12
267
3244
47
41
230
3091
39
84
155
2359
Asthma, unspecified
J45.9 [45562456]
1.8e+00
2.0e+00
2.9e+00
1.0e+50
3.5e+00
2.3e+00
2.2e+00
cases:18.04%
controls:3.43%
cases:11.93%
controls:1.87%
cases:5.20%
controls:0.31%
cases:7.65%
controls:0.00%
cases:7.42%
controls:0.25%
cases:16.25%
controls:1.88%
cases:27.84%
controls:3.97%
59
112
268
3151
39
61
288
3202
17
10
310
3253
25
0
302
3263
23
8
287
3248
45
59
232
3073
54
97
140
2346
Bacteria identified in Blood by Culture
600-7 [3023368]
1.0e+00
2.2e+00
3.5e+00
1.0e+50
3.9e+00
2.3e+00
1.6e+00
cases:14.07%
controls:5.64%
cases:17.74%
controls:2.36%
cases:10.40%
controls:0.34%
cases:5.20%
controls:0.00%
cases:9.35%
controls:0.21%
cases:18.05%
controls:2.14%
cases:24.74%
controls:6.43%
46
184
281
3079
58
77
269
3186
34
11
293
3252
17
0
310
3263
29
7
281
3249
50
67
227
3065
48
157
146
2286
Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
13956-8 [3014162]
2.7e+00
4.6e+00
—
1.0e+50
—
3.9e+00
3.2e+00
cases:10.70%
controls:0.80%
cases:18.96%
controls:0.25%
—
—
cases:2.14%
controls:0.00%
—
—
cases:14.80%
controls:0.35%
cases:15.98%
controls:0.74%
35
26
292
3237
62
8
265
3255
—
7
0
320
3263
—
41
11
236
3121
31
18
163
2425
Differential panel, method unspecified - Blood
69738-3 [42870588]
1.1e+00
2.2e+00
3.2e+00
—
3.6e+00
2.3e+00
1.9e+00
cases:22.02%
controls:8.76%
cases:29.36%
controls:4.54%
cases:20.49%
controls:1.01%
—
—
cases:22.90%
controls:0.83%
cases:31.77%
controls:4.44%
cases:39.18%
controls:8.47%
72
286
255
2977
96
148
231
3115
67
33
260
3230
—
71
27
239
3229
88
139
189
2993
76
207
118
2236
salmeterol and fluticasone
R03AK06 [21603280]
2.1e+00
2.3e+00
2.9e+00
—
2.1e+00
2.4e+00
2.3e+00
cases:22.02%
controls:3.22%
cases:19.27%
controls:2.36%
cases:7.65%
controls:0.46%
—
—
cases:5.48%
controls:0.68%
cases:19.13%
controls:2.14%
cases:24.23%
controls:3.11%
72
105
255
3158
63
77
264
3186
25
15
302
3248
—
17
22
293
3234
53
67
224
3065
47
76
147
2367
prednisolone; oral, parenteral
H02AB06 [21602734]
1.7e+00
2.3e+00
2.6e+00
1.0e+50
2.7e+00
2.5e+00
2.3e+00
cases:41.59%
controls:11.77%
cases:39.45%
controls:6.01%
cases:11.62%
controls:1.01%
cases:3.98%
controls:0.00%
cases:14.52%
controls:1.11%
cases:39.71%
controls:5.14%
cases:57.22%
controls:11.99%
136
384
191
2879
129
196
198
3067
38
33
289
3230
13
0
314
3263
45
36
265
3220
110
161
167
2971
111
293
83
2150
High resolution CT examination of lungs
GD1DD [2001303632]
2.5e+00
3.9e+00
—
1.0e+50
1.0e+50
4.3e+00
3.4e+00
cases:7.03%
controls:0.61%
cases:11.01%
controls:0.25%
—
—
cases:5.81%
controls:0.00%
cases:2.26%
controls:0.00%
cases:13.72%
controls:0.22%
cases:18.56%
controls:0.78%
23
20
304
3243
36
8
291
3255
—
19
0
308
3263
7
0
303
3256
38
7
239
3125
36
19
158
2424
prednisolone
A07EA01 [21600653]
1.7e+00
2.3e+00
2.5e+00
1.0e+50
2.7e+00
2.5e+00
2.3e+00
cases:41.59%
controls:11.77%
cases:39.45%
controls:6.07%
cases:11.62%
controls:1.04%
cases:3.98%
controls:0.00%
cases:14.52%
controls:1.11%
cases:39.71%
controls:5.27%
cases:57.22%
controls:12.03%
136
384
191
2879
129
198
198
3065
38
34
289
3229
13
0
314
3263
45
36
265
3220
110
165
167
2967
111
294
83
2149
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6.8e-01
1.3e+00
2.6e+00
4.2e+00
2.8e+00
1.5e+00
9.7e-01
cases:36.09%
controls:22.31%
cases:35.17%
controls:13.21%
cases:26.61%
controls:2.73%
cases:9.17%
controls:0.15%
cases:30.65%
controls:2.58%
cases:40.43%
controls:13.38%
cases:51.03%
controls:28.41%
118
728
209
2535
115
431
212
2832
87
89
240
3174
30
5
297
3258
95
84
215
3172
112
419
165
2713
99
694
95
1749
tiotropium bromide; inhalant
R03BB04 [21603296]
1.9e+00
2.4e+00
2.3e+00
—
2.5e+00
2.4e+00
2.5e+00
cases:15.60%
controls:2.70%
cases:17.43%
controls:1.84%
cases:5.20%
controls:0.55%
—
—
cases:4.52%
controls:0.40%
cases:15.16%
controls:1.63%
cases:25.26%
controls:2.78%
51
88
276
3175
57
60
270
3203
17
18
310
3245
—
14
13
296
3243
42
51
235
3081
49
68
145
2375
Pneumonia, unspecified
J18.9 [45601123]
2.1e+00
3.0e+00
—
1.0e+50
3.7e+00
2.8e+00
2.3e+00
cases:23.55%
controls:3.65%
cases:21.41%
controls:1.29%
—
—
cases:7.03%
controls:0.00%
cases:6.77%
controls:0.18%
cases:18.41%
controls:1.31%
cases:30.93%
controls:4.50%
77
119
250
3144
70
42
257
3221
—
23
0
304
3263
21
6
289
3250
51
41
226
3091
60
110
134
2333
Flexible bronchoscopy
UGC12 [2001303610]
3.4e+00
4.3e+00
—
1.0e+50
1.0e+50
3.5e+00
2.7e+00
cases:15.60%
controls:0.64%
cases:18.35%
controls:0.31%
—
—
cases:3.98%
controls:0.00%
cases:4.84%
controls:0.00%
cases:7.22%
controls:0.22%
cases:8.25%
controls:0.61%
51
21
276
3242
60
10
267
3253
—
13
0
314
3263
15
0
295
3256
20
7
257
3125
16
15
178
2428
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
1.7e+00
2.3e+00
2.7e+00
1.0e+50
3.1e+00
2.1e+00
1.6e+00
cases:12.54%
controls:2.57%
cases:12.54%
controls:1.41%
cases:5.81%
controls:0.40%
cases:6.12%
controls:0.00%
cases:5.81%
controls:0.28%
cases:12.64%
controls:1.76%
cases:12.89%
controls:2.91%
41
84
286
3179
41
46
286
3217
19
13
308
3250
20
0
307
3263
18
9
292
3247
35
55
242
3077
25
71
169
2372
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
3.0e+00
4.1e+00
1.0e+50
—
—
3.8e+00
2.7e+00
cases:8.87%
controls:0.49%
cases:13.76%
controls:0.28%
cases:4.28%
controls:0.00%
—
—
—
—
cases:12.27%
controls:0.32%
cases:9.79%
controls:0.74%
29
16
298
3247
45
9
282
3254
14
0
313
3263
—
—
34
10
243
3122
19
18
175
2425
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
4.8e-01
1.2e+00
2.4e+00
4.8e+00
2.5e+00
1.3e+00
7.9e-01
cases:44.04%
controls:32.85%
cases:46.48%
controls:20.41%
cases:35.78%
controls:4.84%
cases:18.04%
controls:0.18%
cases:31.94%
controls:3.69%
cases:48.01%
controls:20.40%
cases:62.37%
controls:42.98%
144
1072
183
2191
152
666
175
2597
117
158
210
3105
59
6
268
3257
99
120
211
3136
133
639
144
2493
121
1050
73
1393
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
2.8e+00
4.1e+00
—
1.0e+50
—
3.8e+00
2.6e+00
cases:6.42%
controls:0.40%
cases:8.26%
controls:0.15%
—
—
cases:2.14%
controls:0.00%
—
—
cases:8.30%
controls:0.19%
cases:9.28%
controls:0.78%
21
13
306
3250
27
5
300
3258
—
7
0
320
3263
—
23
6
254
3126
18
19
176
2424
Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
40976-3 [3040853]
2.3e+00
3.9e+00
1.0e+50
—
1.0e+50
3.5e+00
3.5e+00
cases:3.98%
controls:0.40%
cases:8.56%
controls:0.18%
cases:5.20%
controls:0.00%
—
—
cases:8.71%
controls:0.00%
cases:8.66%
controls:0.29%
cases:9.79%
controls:0.33%
13
13
314
3250
28
6
299
3257
17
0
310
3263
—
27
0
283
3256
24
9
253
3123
19
8
175
2435
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
9.1e-01
1.9e+00
3.2e+00
—
3.2e+00
2.2e+00
1.7e+00
cases:25.38%
controls:12.01%
cases:33.64%
controls:6.83%
cases:25.08%
controls:1.38%
—
—
cases:26.13%
controls:1.41%
cases:38.27%
controls:6.58%
cases:47.94%
controls:14.04%
83
392
244
2871
110
223
217
3040
82
45
245
3218
—
81
46
229
3210
106
206
171
2926
93
343
101
2100
Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
38917-1 [3042194]
2.3e+00
4.0e+00
1.0e+50
—
1.0e+50
3.6e+00
3.3e+00
cases:3.67%
controls:0.40%
cases:7.65%
controls:0.15%
cases:4.59%
controls:0.00%
—
—
cases:8.06%
controls:0.00%
cases:8.66%
controls:0.26%
cases:9.79%
controls:0.41%
12
13
315
3250
25
5
302
3258
15
0
312
3263
—
25
0
285
3256
24
8
253
3124
19
10
175
2433
Monocytes/Leukocytes in Blood
26485-3 [3019069]
9.0e-01
1.9e+00
3.2e+00
—
3.2e+00
2.2e+00
1.7e+00
cases:25.38%
controls:12.11%
cases:33.64%
controls:6.80%
cases:25.08%
controls:1.38%
—
—
cases:26.13%
controls:1.41%
cases:38.27%
controls:6.64%
cases:47.94%
controls:14.08%
83
395
244
2868
110
222
217
3041
82
45
245
3218
—
81
46
229
3210
106
208
171
2924
93
344
101
2099
Basophils [#/volume] in Blood
26444-0 [3006315]
9.3e-01
2.0e+00
3.3e+00
—
3.1e+00
2.2e+00
1.7e+00
cases:26.30%
controls:12.38%
cases:34.86%
controls:6.96%
cases:25.38%
controls:1.29%
—
—
cases:24.84%
controls:1.47%
cases:39.71%
controls:6.93%
cases:49.48%
controls:15.51%
86
404
241
2859
114
227
213
3036
83
42
244
3221
—
77
48
233
3208
110
217
167
2915
96
379
98
2064
Monocytes [#/volume] in Blood
26484-6 [3001604]
9.2e-01
2.0e+00
3.3e+00
—
3.1e+00
2.2e+00
1.7e+00
cases:26.30%
controls:12.41%
cases:34.56%
controls:6.96%
cases:25.38%
controls:1.29%
—
—
cases:24.84%
controls:1.50%
cases:39.71%
controls:6.93%
cases:50.00%
controls:15.47%
86
405
241
2858
113
227
214
3036
83
42
244
3221
—
77
49
233
3207
110
217
167
2915
97
378
97
2065
Basophils/Leukocytes in Blood
30180-4 [3022096]
9.0e-01
1.9e+00
3.2e+00
—
3.2e+00
2.2e+00
1.7e+00
cases:25.08%
controls:11.95%
cases:33.64%
controls:6.77%
cases:24.77%
controls:1.38%
—
—
cases:25.81%
controls:1.38%
cases:38.27%
controls:6.61%
cases:47.42%
controls:14.12%
82
390
245
2873
110
221
217
3042
81
45
246
3218
—
80
45
230
3211
106
207
171
2925
92
345
102
2098
Eosinophils [#/volume] in Blood
26449-9 [3013115]
9.3e-01
1.9e+00
3.3e+00
—
3.2e+00
2.1e+00
1.7e+00
cases:27.52%
controls:12.99%
cases:34.86%
controls:7.45%
cases:28.13%
controls:1.47%
—
—
cases:27.10%
controls:1.57%
cases:39.71%
controls:7.22%
cases:50.52%
controls:16.33%
90
424
237
2839
114
243
213
3020
92
48
235
3215
—
84
51
226
3205
110
226
167
2906
98
399
96
2044
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
1.2e+00
2.0e+00
3.0e+00
—
3.0e+00
2.1e+00
1.7e+00
cases:4.89%
controls:1.50%
cases:7.65%
controls:1.07%
cases:5.20%
controls:0.28%
—
—
cases:4.52%
controls:0.25%
cases:7.94%
controls:1.05%
cases:11.86%
controls:2.46%
16
49
311
3214
25
35
302
3228
17
9
310
3254
—
14
8
296
3248
22
33
255
3099
23
60
171
2383
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
8.7e-01
2.0e+00
3.3e+00
—
3.1e+00
2.1e+00
1.6e+00
cases:25.99%
controls:12.78%
cases:35.47%
controls:7.20%
cases:25.69%
controls:1.32%
—
—
cases:24.84%
controls:1.54%
cases:39.71%
controls:7.28%
cases:49.48%
controls:16.17%
85
417
242
2846
116
235
211
3028
84
43
243
3220
—
77
50
233
3206
110
228
167
2904
96
395
98
2048
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
8.5e-01
1.9e+00
3.2e+00
—
3.2e+00
2.1e+00
1.7e+00
cases:24.77%
controls:12.29%
cases:33.03%
controls:6.86%
cases:24.77%
controls:1.35%
—
—
cases:25.16%
controls:1.38%
cases:38.27%
controls:6.99%
cases:47.94%
controls:14.86%
81
401
246
2862
108
224
219
3039
81
44
246
3219
—
78
45
232
3211
106
219
171
2913
93
363
101
2080
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
2.8e+00
4.2e+00
—
1.0e+50
—
3.3e+00
2.6e+00
cases:14.98%
controls:1.10%
cases:21.71%
controls:0.40%
—
—
cases:3.67%
controls:0.00%
—
—
cases:10.83%
controls:0.45%
cases:12.89%
controls:1.11%
49
36
278
3227
71
13
256
3250
—
12
0
315
3263
—
30
14
247
3118
25
27
169
2416
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
9.8e-01
2.1e+00
3.4e+00
—
3.3e+00
1.6e+00
1.4e+00
cases:9.48%
controls:3.77%
cases:7.65%
controls:1.01%
cases:5.20%
controls:0.18%
—
—
cases:4.19%
controls:0.15%
cases:5.05%
controls:1.05%
cases:11.34%
controls:3.03%
31
123
296
3140
25
33
302
3230
17
6
310
3257
—
13
5
297
3251
14
33
263
3099
22
74
172
2369
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
1.1e+00
2.0e+00
3.0e+00
—
2.8e+00
2.1e+00
1.9e+00
cases:4.89%
controls:1.72%
cases:7.95%
controls:1.20%
cases:5.50%
controls:0.28%
—
—
cases:4.19%
controls:0.28%
cases:8.30%
controls:1.09%
cases:13.40%
controls:2.33%
16
56
311
3207
26
39
301
3224
18
9
309
3254
—
13
9
297
3247
23
34
254
3098
26
57
168
2386
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
1.6e+00
2.0e+00
2.3e+00
—
3.5e+00
1.8e+00
1.7e+00
cases:9.79%
controls:2.24%
cases:10.09%
controls:1.56%
cases:3.98%
controls:0.40%
—
—
cases:8.71%
controls:0.28%
cases:8.30%
controls:1.53%
cases:14.43%
controls:3.07%
32
73
295
3190
33
51
294
3212
13
13
314
3250
—
27
9
283
3247
23
48
254
3084
28
75
166
2368
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
1.1e+00
1.9e+00
3.2e+00
—
2.7e+00
2.1e+00
1.9e+00
cases:4.59%
controls:1.56%
cases:7.34%
controls:1.16%
cases:5.50%
controls:0.25%
—
—
cases:3.87%
controls:0.28%
cases:7.94%
controls:1.05%
cases:12.89%
controls:2.25%
15
51
312
3212
24
38
303
3225
18
8
309
3255
—
12
9
298
3247
22
33
255
3099
25
55
169
2388
Predominantly allergic asthma
J45.0 [45557624]
2.4e+00
3.0e+00
—
1.0e+50
—
3.8e+00
3.6e+00
cases:10.09%
controls:1.01%
cases:10.40%
controls:0.58%
—
—
cases:10.09%
controls:0.00%
—
—
cases:15.88%
controls:0.42%
cases:23.20%
controls:0.82%
33
33
294
3230
34
19
293
3244
—
33
0
294
3263
—
44
13
233
3119
45
20
149
2423
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
9.2e-01
1.8e+00
3.0e+00
—
3.2e+00
2.1e+00
1.7e+00
cases:25.38%
controls:11.95%
cases:31.50%
controls:6.77%
cases:22.02%
controls:1.38%
—
—
cases:24.84%
controls:1.38%
cases:37.18%
controls:6.83%
cases:46.91%
controls:14.37%
83
390
244
2873
103
221
224
3042
72
45
255
3218
—
77
45
233
3211
103
214
174
2918
91
351
103
2092
Supplier / Service Provider
OMOP5117446 [33004]
7.6e-02
8.0e-01
1.7e+00
—
3.0e+00
3.5e+00
3.6e+00
cases:29.05%
controls:27.52%
cases:17.13%
controls:8.52%
cases:4.89%
controls:0.89%
—
—
cases:2.90%
controls:0.15%
cases:18.05%
controls:0.64%
cases:37.11%
controls:1.56%
95
898
232
2365
56
278
271
2985
16
29
311
3234
—
9
5
301
3251
50
20
227
3112
72
38
122
2405
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
6.6e-01
1.9e+00
3.7e+00
—
3.7e+00
1.7e+00
1.0e+00
cases:12.54%
controls:6.93%
cases:14.37%
controls:2.45%
cases:5.81%
controls:0.15%
—
—
cases:5.81%
controls:0.15%
cases:11.91%
controls:2.39%
cases:17.53%
controls:7.20%
41
226
286
3037
47
80
280
3183
19
5
308
3258
—
18
5
292
3251
33
75
244
3057
34
176
160
2267
Normoblasts [#/volume] in Blood
715-3 [3021589]
6.1e-01
1.2e+00
2.4e+00
3.6e+00
2.3e+00
1.4e+00
1.1e+00
cases:18.96%
controls:11.25%
cases:24.46%
controls:8.55%
cases:18.96%
controls:2.18%
cases:6.42%
controls:0.18%
cases:18.39%
controls:2.15%
cases:27.44%
controls:8.75%
cases:34.02%
controls:15.23%
62
367
265
2896
80
279
247
2984
62
71
265
3192
21
6
306
3257
57
70
253
3186
76
274
201
2858
66
372
128
2071
montelukast; oral
R03DC03 [21603356]
1.9e+00
2.0e+00
2.1e+00
—
2.2e+00
2.1e+00
2.2e+00
cases:15.90%
controls:2.82%
cases:11.93%
controls:1.87%
cases:2.75%
controls:0.34%
—
—
cases:4.19%
controls:0.46%
cases:13.00%
controls:1.82%
cases:21.65%
controls:3.03%
52
92
275
3171
39
61
288
3202
9
11
318
3252
—
13
15
297
3241
36
57
241
3075
42
74
152
2369
Fungus identified in Specimen by Culture
580-1 [3000494]
2.0e+00
3.9e+00
—
1.0e+50
—
3.9e+00
2.6e+00
cases:13.46%
controls:2.02%
cases:23.55%
controls:0.61%
—
—
cases:4.28%
controls:0.00%
—
—
cases:25.27%
controls:0.70%
cases:25.77%
controls:2.42%
44
66
283
3197
77
20
250
3243
—
14
0
313
3263
—
70
22
207
3110
50
59
144
2384
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
1.0e+00
1.8e+00
2.9e+00
—
3.5e+00
1.9e+00
1.3e+00
cases:16.21%
controls:6.37%
cases:13.46%
controls:2.54%
cases:7.34%
controls:0.43%
—
—
cases:9.03%
controls:0.31%
cases:14.44%
controls:2.52%
cases:19.59%
controls:5.98%
53
208
274
3055
44
83
283
3180
24
14
303
3249
—
28
10
282
3246
40
79
237
3053
38
146
156
2297
Blasts/Leukocytes in Blood
26446-5 [3025159]
1.1e+00
1.9e+00
3.0e+00
—
2.8e+00
1.9e+00
1.6e+00
cases:4.28%
controls:1.41%
cases:7.34%
controls:1.16%
cases:5.20%
controls:0.28%
—
—
cases:4.19%
controls:0.28%
cases:7.22%
controls:1.12%
cases:10.82%
controls:2.46%
14
46
313
3217
24
38
303
3225
17
9
310
3254
—
13
9
297
3247
20
35
257
3097
21
60
173
2383
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
1.0e+00
1.7e+00
3.3e+00
—
3.1e+00
1.8e+00
1.2e+00
cases:7.03%
controls:2.70%
cases:7.65%
controls:1.53%
cases:3.98%
controls:0.15%
—
—
cases:3.87%
controls:0.18%
cases:6.14%
controls:1.05%
cases:10.82%
controls:3.52%
23
88
304
3175
25
50
302
3213
13
5
314
3258
—
12
6
298
3250
17
33
260
3099
21
86
173
2357
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
8.9e-01
1.7e+00
2.9e+00
—
3.2e+00
2.0e+00
1.3e+00
cases:26.61%
controls:12.90%
cases:27.83%
controls:6.62%
cases:21.71%
controls:1.50%
—
—
cases:25.48%
controls:1.41%
cases:33.57%
controls:6.48%
cases:40.21%
controls:15.51%
87
421
240
2842
91
216
236
3047
71
49
256
3214
—
79
46
231
3210
93
203
184
2929
78
379
116
2064
Outpatient Hospital
22 [8756]
6.4e-01
1.9e+00
3.5e+00
—
2.9e+00
1.8e+00
1.1e+00
cases:38.23%
controls:24.58%
cases:31.50%
controls:6.31%
cases:15.29%
controls:0.52%
—
—
cases:10.65%
controls:0.64%
cases:24.91%
controls:5.17%
cases:37.11%
controls:16.17%
125
802
202
2461
103
206
224
3057
50
17
277
3246
—
33
21
277
3235
69
162
208
2970
72
395
122
2048
Otolaryngology
4 [38004449]
1.2e+00
1.7e+00
2.9e+00
—
2.9e+00
1.9e+00
1.2e+00
cases:32.11%
controls:12.84%
cases:21.41%
controls:4.75%
cases:12.84%
controls:0.83%
—
—
cases:16.13%
controls:1.01%
cases:25.63%
controls:4.79%
cases:32.47%
controls:12.16%
105
419
222
2844
70
155
257
3108
42
27
285
3236
—
50
33
260
3223
71
150
206
2982
63
297
131
2146
Physiotherapy
R4110 [2001310233]
9.7e-01
2.0e+00
2.9e+00
1.0e+50
2.6e+00
1.9e+00
1.6e+00
cases:12.84%
controls:5.30%
cases:12.54%
controls:1.96%
cases:3.67%
controls:0.21%
cases:6.12%
controls:0.00%
cases:3.55%
controls:0.28%
cases:11.19%
controls:1.92%
cases:18.04%
controls:4.34%
42
173
285
3090
41
64
286
3199
12
7
315
3256
20
0
307
3263
11
9
299
3247
31
60
246
3072
35
106
159
2337
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
8.8e-01
1.8e+00
2.8e+00
—
2.8e+00
2.0e+00
1.6e+00
cases:29.97%
controls:15.08%
cases:35.17%
controls:8.61%
cases:26.91%
controls:2.30%
—
—
cases:27.10%
controls:2.24%
cases:39.71%
controls:8.21%
cases:52.58%
controls:17.56%
98
492
229
2771
115
281
212
2982
88
75
239
3188
—
84
73
226
3183
110
257
167
2875
102
429
92
2014
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
1.1e+00
1.8e+00
2.6e+00
1.0e+50
2.6e+00
2.1e+00
1.6e+00
cases:7.34%
controls:2.57%
cases:7.65%
controls:1.32%
cases:4.89%
controls:0.40%
cases:2.45%
controls:0.00%
cases:5.81%
controls:0.46%
cases:9.39%
controls:1.31%
cases:10.82%
controls:2.33%
24
84
303
3179
25
43
302
3220
16
13
311
3250
8
0
319
3263
18
15
292
3241
26
41
251
3091
21
57
173
2386
Office Visit
OMOP4822458 [581477]
1.1e+00
2.0e+00
2.6e+00
—
2.9e+00
2.0e+00
1.1e+00
cases:20.18%
controls:7.75%
cases:13.76%
controls:2.02%
cases:2.75%
controls:0.21%
—
—
cases:5.16%
controls:0.31%
cases:11.19%
controls:1.76%
cases:17.01%
controls:6.10%
66
253
261
3010
45
66
282
3197
9
7
318
3256
—
16
10
294
3246
31
55
246
3077
33
149
161
2294
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
1.4e+00
3.6e+00
—
—
—
3.5e+00
3.1e+00
cases:5.50%
controls:1.38%
cases:10.70%
controls:0.34%
—
—
—
—
—
—
cases:11.19%
controls:0.38%
cases:22.16%
controls:1.27%
18
45
309
3218
35
11
292
3252
—
—
—
31
12
246
3120
43
31
151
2412
Nonallergic asthma
J45.1 [45557625]
2.1e+00
3.2e+00
—
1.0e+50
—
3.4e+00
2.8e+00
cases:7.65%
controls:1.04%
cases:7.03%
controls:0.31%
—
—
cases:4.59%
controls:0.00%
—
—
cases:11.19%
controls:0.42%
cases:13.92%
controls:0.94%
25
34
302
3229
23
10
304
3253
—
15
0
312
3263
—
31
13
246
3119
27
23
167
2420
Intravenous
ZX120 [2001311495]
1.6e+00
2.7e+00
—
1.0e+50
2.5e+00
2.7e+00
1.9e+00
cases:6.12%
controls:1.35%
cases:7.03%
controls:0.52%
—
—
cases:1.53%
controls:0.00%
cases:2.26%
controls:0.18%
cases:5.78%
controls:0.42%
cases:8.25%
controls:1.27%
20
44
307
3219
23
17
304
3246
—
5
0
322
3263
7
6
303
3250
16
13
261
3119
16
31
178
2412
Thorax CT examination
GD1AD [2001303618]
2.1e+00
2.9e+00
—
1.0e+50
—
3.6e+00
2.5e+00
cases:5.50%
controls:0.74%
cases:7.34%
controls:0.43%
—
—
cases:4.89%
controls:0.00%
—
—
cases:9.75%
controls:0.29%
cases:10.31%
controls:0.90%
18
24
309
3239
24
14
303
3249
—
16
0
311
3263
—
27
9
250
3123
20
22
174
2421
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
8.2e-01
1.6e+00
2.4e+00
—
2.8e+00
1.6e+00
1.8e+00
cases:7.95%
controls:3.68%
cases:8.87%
controls:1.87%
cases:4.89%
controls:0.46%
—
—
cases:8.06%
controls:0.55%
cases:9.03%
controls:1.92%
cases:14.95%
controls:2.91%
26
120
301
3143
29
61
298
3202
16
15
311
3248
—
25
18
285
3238
25
60
252
3072
29
71
165
2372
Bacterial pneumonia, unspecified
J15.9 [45557621]
2.0e+00
3.7e+00
—
1.0e+50
—
3.1e+00
2.2e+00
cases:6.42%
controls:0.95%
cases:8.26%
controls:0.21%
—
—
cases:3.36%
controls:0.00%
—
—
cases:7.22%
controls:0.35%
cases:9.79%
controls:1.19%
21
31
306
3232
27
7
300
3256
—
11
0
316
3263
—
20
11
257
3121
19
29
175
2414
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
1.4e+00
2.3e+00
3.0e+00
—
—
2.5e+00
1.7e+00
cases:27.22%
controls:8.31%
cases:22.02%
controls:2.73%
cases:5.50%
controls:0.28%
—
—
—
—
cases:19.86%
controls:2.08%
cases:33.51%
controls:8.15%
89
271
238
2992
72
89
255
3174
18
9
309
3254
—
—
55
65
222
3067
65
199
129
2244
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
1.2e+00
1.6e+00
2.6e+00
—
3.0e+00
1.6e+00
1.0e+00
cases:10.09%
controls:3.22%
cases:9.17%
controls:2.05%
cases:3.98%
controls:0.31%
—
—
cases:5.16%
controls:0.28%
cases:9.39%
controls:2.08%
cases:12.37%
controls:4.95%
33
105
294
3158
30
67
297
3196
13
10
314
3253
—
16
9
294
3247
26
65
251
3067
24
121
170
2322
Thoracic and Cardiac Surgery
OMOP4822009 [45756830]
1.7e+00
2.8e+00
—
1.0e+50
—
3.8e+00
2.6e+00
cases:8.56%
controls:1.72%
cases:8.87%
controls:0.61%
—
—
cases:3.36%
controls:0.00%
—
—
cases:11.55%
controls:0.29%
cases:11.34%
controls:0.94%
28
56
299
3207
29
20
298
3243
—
11
0
316
3263
—
32
9
245
3123
22
23
172
2420
salbutamol; inhalant
R03AC02 [21603256]
1.5e+00
1.7e+00
2.2e+00
—
1.8e+00
1.8e+00
1.7e+00
cases:44.04%
controls:14.43%
cases:30.89%
controls:7.32%
cases:10.70%
controls:1.32%
—
—
cases:8.06%
controls:1.38%
cases:32.49%
controls:7.22%
cases:50.52%
controls:15.64%
144
471
183
2792
101
239
226
3024
35
43
292
3220
—
25
45
285
3211
90
226
187
2906
98
382
96
2061
pH of Specimen
17433-4 [3019225]
7.1e-01
1.5e+00
2.9e+00
—
3.1e+00
1.8e+00
1.5e+00
cases:4.59%
controls:2.30%
cases:4.28%
controls:0.98%
cases:2.75%
controls:0.15%
—
—
cases:3.23%
controls:0.15%
cases:5.78%
controls:0.96%
cases:9.28%
controls:2.29%
15
75
312
3188
14
32
313
3231
9
5
318
3258
—
10
5
300
3251
16
30
261
3102
18
56
176
2387
Inpatient Hospital
21 [8717]
7.5e-01
1.9e+00
3.0e+00
—
2.6e+00
1.6e+00
9.5e-01
cases:46.79%
controls:29.30%
cases:39.45%
controls:8.89%
cases:18.65%
controls:1.16%
—
—
cases:13.87%
controls:1.20%
cases:32.13%
controls:8.37%
cases:41.24%
controls:21.41%
153
956
174
2307
129
290
198
2973
61
38
266
3225
—
43
39
267
3217
89
262
188
2870
80
523
114
1920
formoterol and beclometasone
R03AK08 [43534839]
1.5e+00
2.0e+00
1.8e+00
—
2.5e+00
2.3e+00
2.5e+00
cases:3.98%
controls:0.92%
cases:5.81%
controls:0.83%
cases:1.53%
controls:0.25%
—
—
cases:4.19%
controls:0.37%
cases:9.75%
controls:1.09%
cases:15.98%
controls:1.60%
13
30
314
3233
19
27
308
3236
5
8
322
3255
—
13
12
297
3244
27
34
250
3098
31
39
163
2404
doxycycline; oral, parenteral
J01AA02 [21602800]
1.2e+00
2.0e+00
2.2e+00
—
2.3e+00
1.6e+00
1.4e+00
cases:41.59%
controls:17.35%
cases:29.05%
controls:5.33%
cases:2.75%
controls:0.31%
—
—
cases:3.23%
controls:0.34%
cases:19.86%
controls:4.66%
cases:40.21%
controls:14.74%
136
566
191
2697
95
174
232
3089
9
10
318
3253
—
10
11
300
3245
55
146
222
2986
78
360
116
2083
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
1.9e+00
2.8e+00
—
—
—
3.2e+00
2.7e+00
cases:6.73%
controls:1.04%
cases:6.73%
controls:0.43%
—
—
—
—
—
—
cases:6.14%
controls:0.26%
cases:10.82%
controls:0.82%
22
34
305
3229
22
14
305
3249
—
—
—
17
8
260
3124
21
20
173
2423
FVC percent change Respiratory system
69982-7 [42868471]
1.8e+00
2.7e+00
—
—
—
3.1e+00
3.1e+00
cases:11.62%
controls:2.18%
cases:8.56%
controls:0.64%
—
—
—
—
—
—
cases:10.11%
controls:0.48%
cases:22.68%
controls:1.35%
38
71
289
3192
28
21
299
3242
—
—
—
28
15
249
3117
44
33
150
2410
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
1.8e+00
2.7e+00
—
—
—
3.1e+00
3.1e+00
cases:11.62%
controls:2.18%
cases:8.56%
controls:0.64%
—
—
—
—
—
—
cases:10.11%
controls:0.48%
cases:22.68%
controls:1.35%
38
71
289
3192
28
21
299
3242
—
—
—
28
15
249
3117
44
33
150
2410
FEV1 --post bronchodilation
20155-8 [3023550]
1.8e+00
2.7e+00
—
—
—
3.1e+00
3.1e+00
cases:11.62%
controls:2.18%
cases:8.56%
controls:0.64%
—
—
—
—
—
—
cases:10.11%
controls:0.48%
cases:22.68%
controls:1.35%
38
71
289
3192
28
21
299
3242
—
—
—
28
15
249
3117
44
33
150
2410
FEV1/FVC --post bronchodilation
69970-2 [42868459]
1.8e+00
2.7e+00
—
—
—
3.1e+00
3.1e+00
cases:11.62%
controls:2.18%
cases:8.56%
controls:0.64%
—
—
—
—
—
—
cases:10.11%
controls:0.48%
cases:22.68%
controls:1.35%
38
71
289
3192
28
21
299
3242
—
—
—
28
15
249
3117
44
33
150
2410
FEV1 percent change
69983-5 [42868472]
1.8e+00
2.7e+00
—
—
—
3.1e+00
3.1e+00
cases:11.62%
controls:2.18%
cases:8.56%
controls:0.64%
—
—
—
—
—
—
cases:10.11%
controls:0.48%
cases:22.68%
controls:1.35%
38
71
289
3192
28
21
299
3242
—
—
—
28
15
249
3117
44
33
150
2410
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
2.0e+00
3.0e+00
—
—
—
3.0e+00
2.7e+00
cases:9.17%
controls:1.41%
cases:12.84%
controls:0.70%
—
—
—
—
—
—
cases:10.83%
controls:0.61%
cases:16.49%
controls:1.35%
30
46
297
3217
42
23
285
3240
—
—
—
30
19
247
3113
32
33
162
2410
Short blood count panel - Blood
55429-5 [40758558]
9.1e-01
1.5e+00
2.8e+00
1.0e+50
2.6e+00
1.4e+00
1.5e+00
cases:13.15%
controls:5.73%
cases:11.01%
controls:2.70%
cases:8.56%
controls:0.58%
cases:3.06%
controls:0.00%
cases:7.74%
controls:0.64%
cases:11.55%
controls:3.26%
cases:25.77%
controls:7.29%
43
187
284
3076
36
88
291
3175
28
19
299
3244
10
0
317
3263
24
21
286
3235
32
102
245
3030
50
178
144
2265
methylprednisolone; oral, parenteral
H02AB04 [21602732]
1.5e+00
2.6e+00
2.7e+00
—
—
1.8e+00
1.9e+00
cases:7.03%
controls:1.65%
cases:6.12%
controls:0.46%
cases:2.14%
controls:0.15%
—
—
—
—
cases:3.25%
controls:0.57%
cases:7.73%
controls:1.23%
23
54
304
3209
20
15
307
3248
7
5
320
3258
—
—
9
18
268
3114
15
30
179
2413
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.1e-01
7.7e-01
1.9e+00
4.7e+00
2.2e+00
7.1e-01
4.2e-01
cases:42.20%
controls:37.27%
cases:46.48%
controls:28.72%
cases:31.19%
controls:6.19%
cases:16.21%
controls:0.18%
cases:30.97%
controls:4.51%
cases:45.85%
controls:29.41%
cases:61.34%
controls:50.96%
138
1216
189
2047
152
937
175
2326
102
202
225
3061
53
6
274
3257
96
147
214
3109
127
921
150
2211
119
1245
75
1198
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
7.3e-01
1.6e+00
2.6e+00
—
2.5e+00
1.7e+00
1.2e+00
cases:20.80%
controls:11.19%
cases:23.55%
controls:5.70%
cases:10.09%
controls:0.86%
—
—
cases:10.97%
controls:1.01%
cases:22.38%
controls:5.08%
cases:30.41%
controls:11.83%
68
365
259
2898
77
186
250
3077
33
28
294
3235
—
34
33
276
3223
62
159
215
2973
59
289
135
2154
Emergency Room Visit
ER [9203]
9.7e-01
1.9e+00
2.6e+00
1.0e+50
2.2e+00
1.5e+00
1.2e+00
cases:55.96%
controls:32.58%
cases:40.98%
controls:9.65%
cases:16.21%
controls:1.47%
cases:14.07%
controls:0.00%
cases:9.35%
controls:1.17%
cases:34.66%
controls:10.15%
cases:57.22%
controls:29.64%
183
1063
144
2200
134
315
193
2948
53
48
274
3215
46
0
281
3263
29
38
281
3218
96
318
181
2814
111
724
83
1719
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.1e-01
7.5e-01
1.9e+00
4.7e+00
2.2e+00
6.8e-01
4.1e-01
cases:42.51%
controls:37.57%
cases:46.48%
controls:29.11%
cases:31.50%
controls:6.37%
cases:16.21%
controls:0.18%
cases:31.29%
controls:4.61%
cases:45.85%
controls:30.04%
cases:61.34%
controls:51.25%
139
1226
188
2037
152
950
175
2313
103
208
224
3055
53
6
274
3257
97
150
213
3106
127
941
150
2191
119
1252
75
1191
Inpatient Visit
IP [9201]
8.3e-01
1.5e+00
3.7e+00
—
2.4e+00
1.7e+00
5.4e-01
cases:15.60%
controls:7.48%
cases:12.84%
controls:3.34%
cases:7.95%
controls:0.21%
—
—
cases:3.55%
controls:0.34%
cases:14.44%
controls:2.91%
cases:13.40%
controls:8.31%
51
244
276
3019
42
109
285
3154
26
7
301
3256
—
11
11
299
3245
40
91
237
3041
26
203
168
2240
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
2.2e+00
3.4e+00
1.0e+50
—
—
2.5e+00
1.9e+00
cases:14.98%
controls:1.84%
cases:12.84%
controls:0.49%
cases:4.59%
controls:0.00%
—
—
—
—
cases:10.47%
controls:0.96%
cases:15.98%
controls:2.74%
49
60
278
3203
42
16
285
3247
15
0
312
3263
—
—
29
30
248
3102
31
67
163
2376
Bacteria [Presence] in Urine
87829-8 [36304419]
8.4e-01
1.5e+00
2.5e+00
1.0e+50
3.0e+00
1.5e+00
7.6e-01
cases:13.46%
controls:6.31%
cases:12.23%
controls:3.16%
cases:5.50%
controls:0.46%
cases:2.14%
controls:0.00%
cases:6.13%
controls:0.34%
cases:11.55%
controls:2.84%
cases:15.98%
controls:8.19%
44
206
283
3057
40
103
287
3160
18
15
309
3248
7
0
320
3263
19
11
291
3245
32
89
245
3043
31
200
163
2243
nystatin; oral
A07AA02 [21600604]
2.0e+00
2.7e+00
1.0e+50
—
—
2.9e+00
2.4e+00
cases:4.59%
controls:0.64%
cases:4.59%
controls:0.34%
cases:2.14%
controls:0.00%
—
—
—
—
cases:5.05%
controls:0.29%
cases:8.25%
controls:0.78%
15
21
312
3242
15
11
312
3252
7
0
320
3263
—
—
14
9
263
3123
16
19
178
2424
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
8.8e-01
1.4e+00
2.1e+00
—
2.9e+00
1.7e+00
1.0e+00
cases:15.60%
controls:7.14%
cases:13.15%
controls:3.59%
cases:4.28%
controls:0.52%
—
—
cases:8.71%
controls:0.52%
cases:15.52%
controls:3.29%
cases:20.62%
controls:8.76%
51
233
276
3030
43
117
284
3146
14
17
313
3246
—
27
17
283
3239
43
103
234
3029
40
214
154
2229
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
6.1e-01
1.8e+00
3.3e+00
1.0e+50
2.2e+00
1.8e+00
9.3e-01
cases:9.17%
controls:5.18%
cases:12.84%
controls:2.48%
cases:10.09%
controls:0.40%
cases:2.14%
controls:0.00%
cases:5.48%
controls:0.64%
cases:13.00%
controls:2.46%
cases:15.46%
controls:6.75%
30
169
297
3094
42
81
285
3182
33
13
294
3250
7
0
320
3263
17
21
293
3235
36
77
241
3055
30
165
164
2278
triamcinolone and antiinfectives
S02CA04 [21605176]
1.9e+00
2.8e+00
—
—
—
2.6e+00
2.7e+00
cases:2.14%
controls:0.34%
cases:2.45%
controls:0.15%
—
—
—
—
—
—
cases:2.89%
controls:0.22%
cases:6.70%
controls:0.49%
7
11
320
3252
8
5
319
3258
—
—
—
8
7
269
3125
13
12
181
2431
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
8.3e-01
1.5e+00
2.6e+00
1.0e+50
2.7e+00
1.5e+00
7.3e-01
cases:14.07%
controls:6.65%
cases:13.76%
controls:3.46%
cases:6.73%
controls:0.52%
cases:2.45%
controls:0.00%
cases:7.42%
controls:0.52%
cases:12.64%
controls:3.10%
cases:17.01%
controls:8.96%
46
217
281
3046
45
113
282
3150
22
17
305
3246
8
0
319
3263
23
17
287
3239
35
97
242
3035
33
219
161
2224
filgrastim; parenteral
L03AA02 [21603851]
—
3.9e+00
—
—
—
3.0e+00
3.0e+00
—
—
cases:7.03%
controls:0.15%
—
—
—
—
—
—
cases:3.61%
controls:0.19%
cases:4.12%
controls:0.20%
—
23
5
304
3258
—
—
—
10
6
267
3126
8
5
186
2438
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
6.8e-01
1.5e+00
2.4e+00
—
2.5e+00
1.6e+00
1.1e+00
cases:21.41%
controls:12.11%
cases:23.85%
controls:6.34%
cases:11.31%
controls:1.10%
—
—
cases:12.58%
controls:1.14%
cases:23.83%
controls:6.07%
cases:34.54%
controls:14.49%
70
395
257
2868
78
207
249
3056
37
36
290
3227
—
39
37
271
3219
66
190
211
2942
67
354
127
2089
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
5.6e-01
1.5e+00
2.5e+00
—
2.6e+00
1.7e+00
1.0e+00
cases:32.11%
controls:21.33%
cases:32.72%
controls:9.87%
cases:18.96%
controls:1.87%
—
—
cases:13.23%
controls:1.17%
cases:36.46%
controls:9.48%
cases:50.00%
controls:25.95%
105
696
222
2567
107
322
220
2941
62
61
265
3202
—
41
38
269
3218
101
297
176
2835
97
634
97
1809
Infectious Disease
44 [38004484]
1.2e+00
2.5e+00
—
1.0e+50
—
3.4e+00
2.7e+00
cases:6.12%
controls:1.84%
cases:6.73%
controls:0.61%
—
—
cases:9.17%
controls:0.00%
—
—
cases:16.61%
controls:0.64%
cases:22.16%
controls:1.84%
20
60
307
3203
22
20
305
3243
—
30
0
297
3263
—
46
20
231
3112
43
45
151
2398
Internal Medicine
11 [38004456]
9.2e-01
1.8e+00
2.5e+00
—
2.0e+00
1.3e+00
1.3e+00
cases:42.51%
controls:22.83%
cases:34.56%
controls:8.21%
cases:13.46%
controls:1.29%
—
—
cases:8.39%
controls:1.17%
cases:25.99%
controls:8.40%
cases:48.45%
controls:20.63%
139
745
188
2518
113
268
214
2995
44
42
283
3221
—
26
38
284
3218
72
263
205
2869
94
504
100
1939
Spirometry
127783003 [4133840]
2.2e+00
2.2e+00
—
—
—
2.6e+00
2.7e+00
cases:7.03%
controls:0.80%
cases:3.36%
controls:0.37%
—
—
—
—
—
—
cases:4.33%
controls:0.35%
cases:8.76%
controls:0.61%
23
26
304
3237
11
12
316
3251
—
—
—
12
11
265
3121
17
15
177
2428
Haemoptysis
R04.2 [45577777]
2.8e+00
3.7e+00
1.0e+50
—
—
—
3.2e+00
cases:4.89%
controls:0.31%
cases:6.12%
controls:0.15%
cases:3.98%
controls:0.00%
—
—
—
—
—
—
cases:8.25%
controls:0.37%
16
10
311
3253
20
5
307
3258
13
0
314
3263
—
—
—
16
9
178
2434
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
6.2e-01
1.5e+00
3.0e+00
—
3.2e+00
1.5e+00
6.0e-01
cases:18.35%
controls:10.76%
cases:14.98%
controls:3.83%
cases:7.34%
controls:0.40%
—
—
cases:6.13%
controls:0.28%
cases:13.72%
controls:3.45%
cases:18.56%
controls:11.13%
60
351
267
2912
49
125
278
3138
24
13
303
3250
—
19
9
291
3247
38
108
239
3024
36
272
158
2171
Emergency Room and Inpatient Visit
ERIP [262]
5.7e-01
2.0e+00
2.7e+00
1.0e+50
2.5e+00
1.7e+00
9.2e-01
cases:10.40%
controls:6.16%
cases:15.60%
controls:2.42%
cases:7.34%
controls:0.55%
cases:8.56%
controls:0.00%
cases:4.52%
controls:0.40%
cases:14.44%
controls:3.00%
cases:20.62%
controls:9.41%
34
201
293
3062
51
79
276
3184
24
18
303
3245
28
0
299
3263
14
13
296
3243
40
94
237
3038
40
230
154
2213
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
1.6e+00
3.2e+00
—
1.0e+50
—
2.9e+00
2.0e+00
cases:3.67%
controls:0.74%
cases:5.50%
controls:0.25%
—
—
cases:1.53%
controls:0.00%
—
—
cases:2.89%
controls:0.16%
cases:4.12%
controls:0.57%
12
24
315
3239
18
8
309
3255
—
5
0
322
3263
—
8
5
269
3127
8
14
186
2429
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
7.2e-01
1.5e+00
2.4e+00
1.0e+50
2.6e+00
1.5e+00
9.3e-01
cases:19.88%
controls:10.79%
cases:20.80%
controls:5.58%
cases:9.48%
controls:0.95%
cases:2.14%
controls:0.00%
cases:12.26%
controls:1.01%
cases:20.94%
controls:5.46%
cases:28.87%
controls:13.75%
65
352
262
2911
68
182
259
3081
31
31
296
3232
7
0
320
3263
38
33
272
3223
58
171
219
2961
56
336
138
2107
pH of Serum or Plasma
2753-2 [3018418]
7.2e-01
1.4e+00
2.3e+00
—
2.5e+00
1.6e+00
1.1e+00
cases:14.07%
controls:7.39%
cases:14.37%
controls:3.95%
cases:4.89%
controls:0.49%
—
—
cases:6.77%
controls:0.58%
cases:15.16%
controls:3.48%
cases:19.59%
controls:7.74%
46
241
281
3022
47
129
280
3134
16
16
311
3247
—
21
19
289
3237
42
109
235
3023
38
189
156
2254
Extensive body CT
JN4BD [2001310899]
1.8e+00
2.6e+00
—
1.0e+50
—
3.2e+00
2.1e+00
cases:7.95%
controls:1.47%
cases:6.42%
controls:0.52%
—
—
cases:1.53%
controls:0.00%
—
—
cases:3.61%
controls:0.16%
cases:5.15%
controls:0.65%
26
48
301
3215
21
17
306
3246
—
5
0
322
3263
—
10
5
267
3127
10
16
184
2427
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
1.2e+00
1.5e+00
2.4e+00
—
2.9e+00
1.5e+00
7.5e-01
cases:10.09%
controls:3.19%
cases:9.48%
controls:2.27%
cases:3.98%
controls:0.37%
—
—
cases:5.16%
controls:0.31%
cases:8.66%
controls:2.01%
cases:10.82%
controls:5.44%
33
104
294
3159
31
74
296
3189
13
12
314
3251
—
16
10
294
3246
24
63
253
3069
21
133
173
2310
Diffusion capacity of lung
54715006 [4182985]
2.1e+00
2.2e+00
—
—
—
2.8e+00
2.4e+00
cases:4.28%
controls:0.52%
cases:2.45%
controls:0.28%
—
—
—
—
—
—
cases:2.53%
controls:0.16%
cases:4.64%
controls:0.45%
14
17
313
3246
8
9
319
3254
—
—
—
7
5
270
3127
9
11
185
2432
Tissue Pathology biopsy report
66121-5 [40768804]
4.2e-01
1.2e+00
3.5e+00
—
3.0e+00
1.7e+00
5.2e-01
cases:14.07%
controls:9.68%
cases:9.79%
controls:3.16%
cases:5.81%
controls:0.18%
—
—
cases:3.55%
controls:0.18%
cases:10.83%
controls:2.27%
cases:14.43%
controls:9.09%
46
316
281
2947
32
103
295
3160
19
6
308
3257
—
11
6
299
3250
30
71
247
3061
28
222
166
2221
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.4e-01
6.6e-01
2.0e+00
3.7e+00
2.3e+00
7.5e-01
2.5e-01
cases:44.04%
controls:38.25%
cases:43.43%
controls:28.35%
cases:29.05%
controls:5.42%
cases:10.09%
controls:0.28%
cases:31.94%
controls:4.67%
cases:46.57%
controls:29.12%
cases:59.28%
controls:53.13%
144
1248
183
2015
142
925
185
2338
95
177
232
3086
33
9
294
3254
99
152
211
3104
129
912
148
2220
115
1298
79
1145
MCH [Entitic mass]
28539-5 [3035941]
1.9e-01
6.0e-01
1.9e+00
4.1e+00
2.0e+00
6.1e-01
2.2e-01
cases:47.40%
controls:42.81%
cases:49.85%
controls:35.18%
cases:39.76%
controls:8.76%
cases:18.65%
controls:0.37%
cases:34.84%
controls:6.66%
cases:50.90%
controls:36.02%
cases:63.92%
controls:58.82%
155
1397
172
1866
163
1148
164
2115
130
286
197
2977
61
12
266
3251
108
217
202
3039
141
1128
136
2004
124
1437
70
1006
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
1.3e+00
1.5e+00
—
—
3.2e+00
1.9e+00
1.4e+00
cases:3.98%
controls:1.16%
cases:4.28%
controls:0.95%
—
—
—
—
cases:3.55%
controls:0.15%
cases:4.69%
controls:0.73%
cases:7.22%
controls:1.84%
13
38
314
3225
14
31
313
3232
—
—
11
5
299
3251
13
23
264
3109
14
45
180
2398
Platelets [#/volume] in Blood
26515-7 [3007461]
1.8e-01
6.1e-01
1.9e+00
4.1e+00
2.0e+00
6.1e-01
2.2e-01
cases:47.40%
controls:42.84%
cases:49.85%
controls:35.12%
cases:39.76%
controls:8.73%
cases:18.65%
controls:0.37%
cases:34.84%
controls:6.73%
cases:50.90%
controls:36.02%
cases:63.92%
controls:58.66%
155
1398
172
1865
163
1146
164
2117
130
285
197
2978
61
12
266
3251
108
219
202
3037
141
1128
136
2004
124
1433
70
1010
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.8e-01
6.0e-01
1.9e+00
4.1e+00
2.0e+00
6.1e-01
2.2e-01
cases:47.40%
controls:42.84%
cases:49.85%
controls:35.18%
cases:39.76%
controls:8.76%
cases:18.65%
controls:0.37%
cases:34.84%
controls:6.66%
cases:50.90%
controls:36.14%
cases:63.92%
controls:58.82%
155
1398
172
1865
163
1148
164
2115
130
286
197
2977
61
12
266
3251
108
217
202
3039
141
1132
136
2000
124
1437
70
1006
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
8.7e-01
1.9e+00
3.4e+00
—
—
1.9e+00
1.2e+00
cases:10.40%
controls:4.63%
cases:10.70%
controls:1.84%
cases:4.59%
controls:0.15%
—
—
—
—
cases:10.11%
controls:1.72%
cases:16.49%
controls:5.36%
34
151
293
3112
35
60
292
3203
15
5
312
3258
—
—
28
54
249
3078
32
131
162
2312
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.8e-01
6.0e-01
1.9e+00
4.1e+00
2.0e+00
6.1e-01
2.2e-01
cases:47.40%
controls:42.84%
cases:49.85%
controls:35.21%
cases:39.76%
controls:8.76%
cases:18.65%
controls:0.37%
cases:34.84%
controls:6.70%
cases:50.90%
controls:36.11%
cases:63.92%
controls:58.82%
155
1398
172
1865
163
1149
164
2114
130
286
197
2977
61
12
266
3251
108
218
202
3038
141
1131
136
2001
124
1437
70
1006
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.8e-01
6.0e-01
1.9e+00
4.1e+00
2.0e+00
6.1e-01
2.2e-01
cases:47.40%
controls:42.84%
cases:49.85%
controls:35.24%
cases:39.76%
controls:8.76%
cases:18.65%
controls:0.37%
cases:34.84%
controls:6.70%
cases:50.90%
controls:36.14%
cases:63.92%
controls:58.82%
155
1398
172
1865
163
1150
164
2113
130
286
197
2977
61
12
266
3251
108
218
202
3038
141
1132
136
2000
124
1437
70
1006
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.9e-01
6.0e-01
1.9e+00
4.1e+00
2.0e+00
6.0e-01
2.1e-01
cases:47.40%
controls:42.81%
cases:49.85%
controls:35.24%
cases:39.76%
controls:8.76%
cases:18.65%
controls:0.37%
cases:34.84%
controls:6.70%
cases:50.90%
controls:36.17%
cases:63.92%
controls:58.94%
155
1397
172
1866
163
1150
164
2113
130
286
197
2977
61
12
266
3251
108
218
202
3038
141
1133
136
1999
124
1440
70
1003
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
1.3e+00
1.6e+00
—
—
3.0e+00
1.9e+00
1.6e+00
cases:3.98%
controls:1.10%
cases:3.67%
controls:0.80%
—
—
—
—
cases:2.90%
controls:0.15%
cases:3.61%
controls:0.57%
cases:6.70%
controls:1.47%
13
36
314
3227
12
26
315
3237
—
—
9
5
301
3251
10
18
267
3114
13
36
181
2407
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
2.6e-01
6.5e-01
1.9e+00
4.1e+00
1.9e+00
7.4e-01
3.4e-01
cases:32.72%
controls:27.21%
cases:35.78%
controls:22.46%
cases:28.44%
controls:5.73%
cases:12.84%
controls:0.25%
cases:23.87%
controls:4.48%
cases:37.91%
controls:22.54%
cases:46.39%
controls:38.07%
107
888
220
2375
117
733
210
2530
93
187
234
3076
42
8
285
3255
74
146
236
3110
105
706
172
2426
90
930
104
1513
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.8e-01
6.0e-01
1.9e+00
4.1e+00
2.0e+00
6.1e-01
2.1e-01
cases:47.40%
controls:42.87%
cases:49.85%
controls:35.27%
cases:39.76%
controls:8.80%
cases:18.65%
controls:0.37%
cases:34.84%
controls:6.73%
cases:50.90%
controls:36.14%
cases:63.92%
controls:58.86%
155
1399
172
1864
163
1151
164
2112
130
287
197
2976
61
12
266
3251
108
219
202
3037
141
1132
136
2000
124
1438
70
1005
enoxaparin; parenteral
B01AB05 [21600976]
5.9e-01
1.2e+00
2.5e+00
—
2.7e+00
2.0e+00
9.1e-01
cases:9.48%
controls:5.49%
cases:5.50%
controls:1.72%
cases:2.45%
controls:0.21%
—
—
cases:3.87%
controls:0.28%
cases:10.47%
controls:1.53%
cases:10.82%
controls:4.67%
31
179
296
3084
18
56
309
3207
8
7
319
3256
—
12
9
298
3247
29
48
248
3084
21
114
173
2329
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.0e-01
6.4e-01
1.8e+00
4.2e+00
2.0e+00
5.5e-01
2.9e-01
cases:45.26%
controls:40.48%
cases:48.32%
controls:32.91%
cases:34.56%
controls:7.88%
cases:17.74%
controls:0.34%
cases:32.58%
controls:5.93%
cases:46.93%
controls:33.88%
cases:62.37%
controls:55.34%
148
1321
179
1942
158
1074
169
2189
113
257
214
3006
58
11
269
3252
101
193
209
3063
130
1061
147
2071
121
1352
73
1091
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
7.7e-01
1.4e+00
2.8e+00
1.0e+50
2.8e+00
1.4e+00
6.0e-01
cases:18.04%
controls:9.22%
cases:15.90%
controls:4.63%
cases:7.65%
controls:0.49%
cases:2.75%
controls:0.00%
cases:7.74%
controls:0.49%
cases:15.52%
controls:4.28%
cases:19.07%
controls:11.46%
59
301
268
2962
52
151
275
3112
25
16
302
3247
9
0
318
3263
24
16
286
3240
43
134
234
2998
37
280
157
2163
moxifloxacin; oral, parenteral
J01MA14 [21603021]
2.8e+00
—
1.0e+50
—
—
3.6e+00
2.7e+00
cases:14.37%
controls:1.04%
—
—
cases:2.45%
controls:0.00%
—
—
—
—
cases:7.58%
controls:0.22%
cases:10.82%
controls:0.78%
47
34
280
3229
—
8
0
319
3263
—
—
21
7
256
3125
21
19
173
2424
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
8.6e-01
1.4e+00
2.7e+00
1.0e+50
2.8e+00
1.4e+00
5.8e-01
cases:16.82%
controls:7.91%
cases:15.29%
controls:4.20%
cases:7.65%
controls:0.55%
cases:2.75%
controls:0.00%
cases:8.06%
controls:0.55%
cases:13.72%
controls:3.93%
cases:18.04%
controls:10.97%
55
258
272
3005
50
137
277
3126
25
18
302
3245
9
0
318
3263
25
18
285
3238
38
123
239
3009
35
268
159
2175
Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection
34645-2 [3031478]
2.8e+00
—
1.0e+50
—
1.0e+50
3.0e+00
3.2e+00
cases:3.98%
controls:0.25%
—
—
cases:5.81%
controls:0.00%
—
—
cases:5.48%
controls:0.00%
cases:5.05%
controls:0.26%
cases:6.70%
controls:0.29%
13
8
314
3255
—
19
0
308
3263
—
17
0
293
3256
14
8
263
3124
13
7
181
2436
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
1.7e-01
5.3e-01
1.7e+00
4.5e+00
1.8e+00
5.0e-01
8.7e-02
cases:35.17%
controls:31.47%
cases:34.56%
controls:23.66%
cases:24.77%
controls:5.46%
cases:11.93%
controls:0.15%
cases:20.65%
controls:4.18%
cases:33.94%
controls:23.69%
cases:45.36%
controls:43.23%
115
1027
212
2236
113
772
214
2491
81
178
246
3085
39
5
288
3258
64
136
246
3120
94
742
183
2390
88
1056
106
1387
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
1.7e+00
2.4e+00
—
—
—
2.7e+00
2.2e+00
cases:12.54%
controls:2.64%
cases:9.48%
controls:0.95%
—
—
—
—
—
—
cases:9.39%
controls:0.67%
cases:18.56%
controls:2.37%
41
86
286
3177
31
31
296
3232
—
—
—
26
21
251
3111
36
58
158
2385
calcium (different salts in combination); oral
A12AA20 [21600872]
1.2e+00
1.5e+00
1.1e+00
—
1.5e+00
2.0e+00
1.8e+00
cases:20.49%
controls:7.51%
cases:20.49%
controls:5.55%
cases:4.89%
controls:1.65%
—
—
cases:7.42%
controls:1.78%
cases:32.49%
controls:6.03%
cases:36.08%
controls:8.92%
67
245
260
3018
67
181
260
3082
16
54
311
3209
—
23
58
287
3198
90
189
187
2943
70
218
124
2225
Chronic obstructive pulmonary disease with acute lower respiratory infection
J44.0 [45601131]
1.8e+00
2.4e+00
—
1.0e+50
—
2.9e+00
1.9e+00
cases:3.67%
controls:0.61%
cases:3.06%
controls:0.28%
—
—
cases:2.14%
controls:0.00%
—
—
cases:4.33%
controls:0.26%
cases:4.64%
controls:0.74%
12
20
315
3243
10
9
317
3254
—
7
0
320
3263
—
12
8
265
3124
9
18
185
2425
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
8.2e-01
1.4e+00
3.0e+00
1.0e+50
2.6e+00
1.2e+00
4.6e-01
cases:11.31%
controls:5.30%
cases:8.56%
controls:2.24%
cases:4.59%
controls:0.25%
cases:1.83%
controls:0.00%
cases:2.90%
controls:0.21%
cases:5.78%
controls:1.88%
cases:9.79%
controls:6.39%
37
173
290
3090
28
73
299
3190
15
8
312
3255
6
0
321
3263
9
7
301
3249
16
59
261
3073
19
156
175
2287
pH of Capillary blood
2745-8 [3009343]
1.3e+00
1.5e+00
—
—
3.1e+00
1.7e+00
1.4e+00
cases:3.98%
controls:1.16%
cases:4.28%
controls:0.95%
—
—
—
—
cases:3.23%
controls:0.15%
cases:3.97%
controls:0.73%
cases:6.70%
controls:1.76%
13
38
314
3225
14
31
313
3232
—
—
10
5
300
3251
11
23
266
3109
13
43
181
2400
itraconazole; oral, parenteral
J02AC02 [21603081]
1.1e+00
2.4e+00
—
1.0e+50
—
4.0e+00
2.5e+00
cases:2.45%
controls:0.83%
cases:3.06%
controls:0.28%
—
—
cases:2.45%
controls:0.00%
—
—
cases:9.75%
controls:0.19%
cases:8.76%
controls:0.78%
8
27
319
3236
10
9
317
3254
—
8
0
319
3263
—
27
6
250
3126
17
19
177
2424
formoterol and fluticasone
R03AK11 [44819166]
2.6e+00
2.0e+00
—
—
—
2.3e+00
2.0e+00
cases:3.06%
controls:0.25%
cases:1.83%
controls:0.25%
—
—
—
—
—
—
cases:2.53%
controls:0.26%
cases:3.09%
controls:0.45%
10
8
317
3255
6
8
321
3255
—
—
—
7
8
270
3124
6
11
188
2432
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
1.9e+00
2.3e+00
—
—
—
2.6e+00
1.9e+00
cases:5.50%
controls:0.83%
cases:4.28%
controls:0.43%
—
—
—
—
—
—
cases:5.42%
controls:0.42%
cases:7.22%
controls:1.11%
18
27
309
3236
14
14
313
3249
—
—
—
15
13
262
3119
14
27
180
2416
Bone marrow biopsy
XW000 [2001310618]
2.4e+00
3.6e+00
1.0e+50
—
1.0e+50
—
2.8e+00
cases:4.89%
controls:0.46%
cases:5.50%
controls:0.15%
cases:2.14%
controls:0.00%
—
—
cases:1.94%
controls:0.00%
—
—
cases:6.19%
controls:0.41%
16
15
311
3248
18
5
309
3258
7
0
320
3263
—
6
0
304
3256
—
12
10
182
2433
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
7.9e-01
1.4e+00
2.4e+00
—
2.4e+00
9.7e-01
8.2e-01
cases:14.68%
controls:7.26%
cases:11.31%
controls:3.06%
cases:3.98%
controls:0.37%
—
—
cases:3.87%
controls:0.37%
cases:7.22%
controls:2.87%
cases:17.01%
controls:8.27%
48
237
279
3026
37
100
290
3163
13
12
314
3251
—
12
12
298
3244
20
90
257
3042
33
202
161
2241
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
3.4e-01
7.6e-01
1.7e+00
3.7e+00
1.9e+00
7.0e-01
3.2e-01
cases:36.70%
controls:29.14%
cases:40.37%
controls:24.03%
cases:25.08%
controls:5.70%
cases:9.79%
controls:0.28%
cases:22.58%
controls:4.36%
cases:39.35%
controls:24.30%
cases:48.97%
controls:41.18%
120
951
207
2312
132
784
195
2479
82
186
245
3077
32
9
295
3254
70
142
240
3114
109
761
168
2371
95
1006
99
1437
Rhinopharyngoscopy
UDH02 [2001301680]
1.5e+00
2.9e+00
—
—
—
3.6e+00
2.2e+00
cases:2.45%
controls:0.55%
cases:2.75%
controls:0.15%
—
—
—
—
—
—
cases:5.42%
controls:0.16%
cases:5.67%
controls:0.65%
8
18
319
3245
9
5
318
3258
—
—
—
15
5
262
3127
11
16
183
2427
Bacteria identified in Isolate by Culture
43409-2 [3042936]
1.4e+00
2.7e+00
—
—
—
2.8e+00
1.8e+00
cases:10.09%
controls:2.79%
cases:14.07%
controls:1.04%
—
—
—
—
—
—
cases:12.27%
controls:0.86%
cases:14.95%
controls:2.91%
33
91
294
3172
46
34
281
3229
—
—
—
34
27
243
3105
29
71
165
2372
fluticasone; inhalant
R03BA05 [21603288]
1.8e+00
1.7e+00
1.8e+00
—
—
1.8e+00
1.6e+00
cases:14.07%
controls:2.67%
cases:7.95%
controls:1.56%
cases:2.14%
controls:0.37%
—
—
—
—
cases:6.86%
controls:1.25%
cases:11.34%
controls:2.50%
46
87
281
3176
26
51
301
3212
7
12
320
3251
—
—
19
39
258
3093
22
61
172
2382
Leukocytes [#/volume] in Urine
30405-5 [3018095]
8.2e-01
1.3e+00
2.6e+00
1.0e+50
2.7e+00
1.2e+00
5.3e-01
cases:17.43%
controls:8.52%
cases:15.29%
controls:4.72%
cases:7.95%
controls:0.61%
cases:2.75%
controls:0.00%
cases:8.06%
controls:0.61%
cases:14.08%
controls:4.73%
cases:19.07%
controls:12.16%
57
278
270
2985
50
154
277
3109
26
20
301
3243
9
0
318
3263
25
20
285
3236
39
148
238
2984
37
297
157
2146
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
3.9e-01
1.4e+00
2.5e+00
—
2.5e+00
1.4e+00
7.2e-01
cases:21.10%
controls:15.32%
cases:24.16%
controls:6.96%
cases:12.84%
controls:1.16%
—
—
cases:7.42%
controls:0.64%
cases:23.10%
controls:7.02%
cases:32.99%
controls:19.40%
69
500
258
2763
79
227
248
3036
42
38
285
3225
—
23
21
287
3235
64
220
213
2912
64
474
130
1969
Bacterial infection, unspecified
A49.9 [45590816]
1.9e+00
2.9e+00
—
—
—
2.2e+00
1.6e+00
cases:6.12%
controls:1.01%
cases:7.03%
controls:0.43%
—
—
—
—
—
—
cases:4.33%
controls:0.51%
cases:6.19%
controls:1.27%
20
33
307
3230
23
14
304
3249
—
—
—
12
16
265
3116
12
31
182
2412
CBC panel - Blood by Automated count
58410-2 [40761511]
3.3e-01
6.6e-01
1.6e+00
3.8e+00
1.7e+00
5.8e-01
3.9e-01
cases:43.73%
controls:35.76%
cases:36.39%
controls:22.80%
cases:20.80%
controls:4.81%
cases:9.17%
controls:0.21%
cases:17.74%
controls:3.65%
cases:33.94%
controls:22.29%
cases:56.19%
controls:46.38%
143
1167
184
2096
119
744
208
2519
68
157
259
3106
30
7
297
3256
55
119
255
3137
94
698
183
2434
109
1133
85
1310
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
4.2e-01
1.3e+00
2.4e+00
—
2.5e+00
1.3e+00
9.5e-01
cases:10.70%
controls:7.32%
cases:10.40%
controls:2.94%
cases:5.81%
controls:0.58%
—
—
cases:7.74%
controls:0.68%
cases:12.27%
controls:3.61%
cases:19.59%
controls:8.60%
35
239
292
3024
34
96
293
3167
19
19
308
3244
—
24
22
286
3234
34
113
243
3019
38
210
156
2233
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
2.0e+00
2.9e+00
—
—
—
—
3.6e+00
cases:4.28%
controls:0.61%
cases:2.75%
controls:0.15%
—
—
—
—
—
—
—
—
cases:12.89%
controls:0.41%
14
20
313
3243
9
5
318
3258
—
—
—
—
25
10
169
2433
salmeterol; inhalant
R03AC12 [21603266]
2.2e+00
2.0e+00
—
—
—
2.2e+00
2.2e+00
cases:3.36%
controls:0.40%
cases:2.14%
controls:0.31%
—
—
—
—
—
—
cases:2.53%
controls:0.29%
cases:3.09%
controls:0.37%
11
13
316
3250
7
10
320
3253
—
—
—
7
9
270
3123
6
9
188
2434
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
7.9e-01
1.4e+00
2.1e+00
—
1.8e+00
1.3e+00
1.1e+00
cases:15.90%
controls:7.94%
cases:10.70%
controls:2.91%
cases:3.98%
controls:0.49%
—
—
cases:2.90%
controls:0.49%
cases:10.83%
controls:3.26%
cases:19.59%
controls:7.65%
52
259
275
3004
35
95
292
3168
13
16
314
3247
—
9
16
301
3240
30
102
247
3030
38
187
156
2256
ciclosporin; oral, parenteral
L04AD01 [21603924]
1.8e+00
2.5e+00
—
—
—
2.8e+00
3.2e+00
cases:1.83%
controls:0.31%
cases:3.98%
controls:0.34%
—
—
—
—
—
—
cases:4.33%
controls:0.29%
cases:5.67%
controls:0.25%
6
10
321
3253
13
11
314
3252
—
—
—
12
9
265
3123
11
6
183
2437
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
1.3e+00
2.4e+00
2.3e+00
—
—
1.4e+00
1.0e+00
cases:10.09%
controls:2.88%
cases:11.01%
controls:1.13%
cases:2.14%
controls:0.21%
—
—
—
—
cases:4.33%
controls:1.09%
cases:8.25%
controls:3.19%
33
94
294
3169
36
37
291
3226
7
7
320
3256
—
—
12
34
265
3098
16
78
178
2365
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
1.2e+00
2.7e+00
—
1.0e+50
—
2.6e+00
2.0e+00
cases:7.65%
controls:2.54%
cases:13.15%
controls:1.04%
—
—
cases:4.89%
controls:0.00%
—
—
cases:14.44%
controls:1.28%
cases:20.62%
controls:3.36%
25
83
302
3180
43
34
284
3229
—
16
0
311
3263
—
40
40
237
3092
40
82
154
2361
tacrolimus; oral, parenteral
L04AD02 [21603925]
2.8e+00
3.2e+00
1.0e+50
—
—
—
2.4e+00
cases:2.45%
controls:0.15%
cases:3.67%
controls:0.15%
cases:1.53%
controls:0.00%
—
—
—
—
—
—
cases:2.58%
controls:0.25%
8
5
319
3258
12
5
315
3258
5
0
322
3263
—
—
—
5
6
189
2437
salbutamol and ipratropium bromide
R03AL02 [43534844]
—
2.5e+00
—
—
—
3.0e+00
2.9e+00
—
—
cases:1.83%
controls:0.15%
—
—
—
—
—
—
cases:3.61%
controls:0.19%
cases:5.67%
controls:0.33%
—
6
5
321
3258
—
—
—
10
6
267
3126
11
8
183
2435
Bronchiectasis
J47 [45605889]
3.6e+00
—
—
1.0e+50
1.0e+50
—
4.7e+00
cases:7.65%
controls:0.21%
—
—
—
—
cases:5.50%
controls:0.00%
cases:4.52%
controls:0.00%
—
—
cases:18.56%
controls:0.20%
25
7
302
3256
—
—
18
0
309
3263
14
0
296
3256
—
36
5
158
2438
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
1.3e+00
2.8e+00
—
1.0e+50
—
2.4e+00
1.9e+00
cases:6.73%
controls:1.90%
cases:10.40%
controls:0.74%
—
—
cases:2.75%
controls:0.00%
—
—
cases:10.47%
controls:1.09%
cases:14.43%
controls:2.54%
22
62
305
3201
34
24
293
3239
—
9
0
318
3263
—
29
34
248
3098
28
62
166
2381
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
1.2e+00
2.5e+00
1.0e+50
1.0e+50
—
2.7e+00
1.9e+00
cases:7.65%
controls:2.54%
cases:8.87%
controls:0.77%
cases:3.06%
controls:0.00%
cases:3.67%
controls:0.00%
—
—
cases:6.50%
controls:0.45%
cases:10.82%
controls:1.84%
25
83
302
3180
29
25
298
3238
10
0
317
3263
12
0
315
3263
—
18
14
259
3118
21
45
173
2398
fluconazole; oral, parenteral
J02AC01 [21603080]
1.3e+00
1.9e+00
2.6e+00
—
—
1.3e+00
1.1e+00
cases:13.46%
controls:4.23%
cases:8.26%
controls:1.29%
cases:2.45%
controls:0.18%
—
—
—
—
cases:5.05%
controls:1.37%
cases:10.82%
controls:3.77%
44
138
283
3125
27
42
300
3221
8
6
319
3257
—
—
14
43
263
3089
21
92
173
2351
Osmolality of Urine
2695-5 [3026782]
6.0e-01
1.2e+00
3.3e+00
1.0e+50
2.6e+00
1.2e+00
5.4e-01
cases:9.48%
controls:5.42%
cases:6.42%
controls:2.02%
cases:3.98%
controls:0.15%
cases:2.14%
controls:0.00%
cases:3.87%
controls:0.31%
cases:5.42%
controls:1.76%
cases:8.76%
controls:5.32%
31
177
296
3086
21
66
306
3197
13
5
314
3258
7
0
320
3263
12
10
298
3246
15
55
262
3077
17
130
177
2313
Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection
29257-3 [3002482]
2.4e+00
—
1.0e+50
—
1.0e+50
2.9e+00
2.8e+00
cases:3.98%
controls:0.37%
—
—
cases:6.73%
controls:0.00%
—
—
cases:6.77%
controls:0.00%
cases:5.05%
controls:0.29%
cases:7.22%
controls:0.45%
13
12
314
3251
—
22
0
305
3263
—
21
0
289
3256
14
9
263
3123
14
11
180
2432
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
1.2e+00
2.7e+00
—
1.0e+50
—
2.5e+00
1.8e+00
cases:6.12%
controls:1.96%
cases:9.79%
controls:0.74%
—
—
cases:2.14%
controls:0.00%
—
—
cases:10.47%
controls:0.96%
cases:12.89%
controls:2.37%
20
64
307
3199
32
24
295
3239
—
7
0
320
3263
—
29
30
248
3102
25
58
169
2385
metronidazole and furazolidone
P01AB51 [45893518]
1.7e+00
2.8e+00
—
—
—
2.6e+00
2.7e+00
cases:1.83%
controls:0.34%
cases:2.45%
controls:0.15%
—
—
—
—
—
—
cases:2.89%
controls:0.22%
cases:6.70%
controls:0.49%
6
11
321
3252
8
5
319
3258
—
—
—
8
7
269
3125
13
12
181
2431
nystatin
D01AA01 [21601911]
1.7e+00
2.8e+00
—
—
—
2.6e+00
2.7e+00
cases:1.83%
controls:0.34%
cases:2.45%
controls:0.15%
—
—
—
—
—
—
cases:2.89%
controls:0.22%
cases:6.70%
controls:0.49%
6
11
321
3252
8
5
319
3258
—
—
—
8
7
269
3125
13
12
181
2431
nystatin; vaginal
G01AA01 [21602363]
1.7e+00
2.8e+00
—
—
—
2.6e+00
2.7e+00
cases:1.83%
controls:0.34%
cases:2.45%
controls:0.15%
—
—
—
—
—
—
cases:2.89%
controls:0.22%
cases:6.70%
controls:0.49%
6
11
321
3252
8
5
319
3258
—
—
—
8
7
269
3125
13
12
181
2431
Chronic maxillary sinusitis
J32.0 [45586667]
2.1e+00
2.7e+00
—
1.0e+50
—
3.2e+00
1.5e+00
cases:6.42%
controls:0.86%
cases:4.89%
controls:0.34%
—
—
cases:1.83%
controls:0.00%
—
—
cases:5.42%
controls:0.22%
cases:4.12%
controls:0.94%
21
28
306
3235
16
11
311
3252
—
6
0
321
3263
—
15
7
262
3125
8
23
186
2420
Abdominal ultrasound examination
JN3AE [2001305555]
1.4e+00
2.1e+00
—
1.0e+50
—
2.5e+00
2.0e+00
cases:6.73%
controls:1.75%
cases:5.20%
controls:0.67%
—
—
cases:1.83%
controls:0.00%
—
—
cases:3.25%
controls:0.29%
cases:8.76%
controls:1.23%
22
57
305
3206
17
22
310
3241
—
6
0
321
3263
—
9
9
268
3123
17
30
177
2413
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
5.9e-01
1.3e+00
2.0e+00
—
2.1e+00
1.6e+00
9.5e-01
cases:10.09%
controls:5.88%
cases:8.87%
controls:2.57%
cases:3.67%
controls:0.49%
—
—
cases:2.58%
controls:0.34%
cases:11.55%
controls:2.52%
cases:17.53%
controls:7.61%
33
192
294
3071
29
84
298
3179
12
16
315
3247
—
8
11
302
3245
32
79
245
3053
34
186
160
2257
roxithromycin; oral
J01FA06 [21602974]
1.7e+00
2.5e+00
—
—
—
2.0e+00
1.7e+00
cases:14.68%
controls:3.13%
cases:8.87%
controls:0.77%
—
—
—
—
—
—
cases:4.33%
controls:0.61%
cases:10.82%
controls:2.21%
48
102
279
3161
29
25
298
3238
—
—
—
12
19
265
3113
21
54
173
2389
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
1.1e+00
1.7e+00
2.1e+00
—
—
1.8e+00
1.2e+00
cases:16.21%
controls:6.31%
cases:8.87%
controls:1.72%
cases:2.45%
controls:0.31%
—
—
—
—
cases:8.30%
controls:1.50%
cases:15.98%
controls:5.32%
53
206
274
3057
29
56
298
3207
8
10
319
3253
—
—
23
47
254
3085
31
130
163
2313
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
8.6e-01
1.7e+00
—
—
3.0e+00
2.0e+00
1.2e+00
cases:4.59%
controls:1.99%
cases:5.81%
controls:1.10%
—
—
—
—
cases:2.90%
controls:0.15%
cases:5.05%
controls:0.73%
cases:8.25%
controls:2.66%
15
65
312
3198
19
36
308
3227
—
—
9
5
301
3251
14
23
263
3109
16
65
178
2378
Emergency Medicine
93 [38004510]
5.5e-01
1.3e+00
2.0e+00
1.0e+50
1.9e+00
1.2e+00
8.1e-01
cases:25.69%
controls:16.58%
cases:24.16%
controls:7.81%
cases:8.87%
controls:1.35%
cases:5.81%
controls:0.00%
cases:6.45%
controls:0.98%
cases:22.38%
controls:8.24%
cases:38.66%
controls:21.82%
84
541
243
2722
79
255
248
3008
29
44
298
3219
19
0
308
3263
20
32
290
3224
62
258
215
2874
75
533
119
1910
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
1.4e+00
1.9e+00
2.3e+00
—
—
2.1e+00
9.5e-01
cases:9.79%
controls:2.70%
cases:6.12%
controls:0.95%
cases:2.14%
controls:0.21%
—
—
—
—
cases:3.61%
controls:0.45%
cases:6.70%
controls:2.70%
32
88
295
3175
20
31
307
3232
7
7
320
3256
—
—
10
14
267
3118
13
66
181
2377
Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
76080-1 [46235759]
—
2.6e+00
1.0e+50
1.0e+50
1.0e+50
3.1e+00
1.9e+00
—
—
cases:2.45%
controls:0.18%
cases:1.53%
controls:0.00%
cases:1.53%
controls:0.00%
cases:2.90%
controls:0.00%
cases:3.97%
controls:0.19%
cases:5.67%
controls:0.86%
—
8
6
319
3257
5
0
322
3263
5
0
322
3263
9
0
301
3256
11
6
266
3126
11
21
183
2422
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
1.2e+00
1.4e+00
2.2e+00
—
2.8e+00
1.1e+00
6.9e-01
cases:6.12%
controls:1.87%
cases:4.28%
controls:1.10%
cases:2.45%
controls:0.28%
—
—
cases:2.90%
controls:0.18%
cases:2.89%
controls:0.99%
cases:6.19%
controls:3.19%
20
61
307
3202
14
36
313
3227
8
9
319
3254
—
9
6
301
3250
8
31
269
3101
12
78
182
2365
Base excess in Venous blood by calculation
1927-3 [3002032]
1.2e+00
1.4e+00
2.3e+00
—
2.7e+00
9.9e-01
6.9e-01
cases:6.12%
controls:1.87%
cases:4.28%
controls:1.13%
cases:2.45%
controls:0.25%
—
—
cases:2.58%
controls:0.18%
cases:2.53%
controls:0.96%
cases:6.19%
controls:3.19%
20
61
307
3202
14
37
313
3226
8
8
319
3255
—
8
6
302
3250
7
30
270
3102
12
78
182
2365
Band form neutrophils/Leukocytes in Blood
26508-2 [3004809]
1.8e+00
3.0e+00
1.0e+50
—
—
2.8e+00
1.3e+00
cases:2.45%
controls:0.40%
cases:3.98%
controls:0.21%
cases:2.14%
controls:0.00%
—
—
—
—
cases:3.97%
controls:0.26%
cases:2.58%
controls:0.74%
8
13
319
3250
13
7
314
3256
7
0
320
3263
—
—
11
8
266
3124
5
18
189
2425
antibiotics in combination with corticosteroids
D01AA20 [21601918]
1.4e+00
2.0e+00
—
—
—
2.2e+00
1.9e+00
cases:4.28%
controls:1.07%
cases:2.75%
controls:0.37%
—
—
—
—
—
—
cases:3.25%
controls:0.38%
cases:8.25%
controls:1.27%
14
35
313
3228
9
12
318
3251
—
—
—
9
12
268
3120
16
31
178
2412
sulfadiazine and trimethoprim
J01EE02 [21602962]
1.4e+00
2.1e+00
1.0e+50
—
1.0e+50
2.1e+00
1.9e+00
cases:8.87%
controls:2.33%
cases:5.50%
controls:0.70%
cases:2.75%
controls:0.00%
—
—
cases:1.61%
controls:0.00%
cases:6.14%
controls:0.77%
cases:13.92%
controls:2.33%
29
76
298
3187
18
23
309
3240
9
0
318
3263
—
5
0
305
3256
17
24
260
3108
27
57
167
2386
Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection
92695-6 [37019628]
1.3e+00
2.8e+00
—
—
—
2.8e+00
2.0e+00
cases:1.53%
controls:0.43%
cases:2.45%
controls:0.15%
—
—
—
—
—
—
cases:2.53%
controls:0.16%
cases:3.09%
controls:0.45%
5
14
322
3249
8
5
319
3258
—
—
—
7
5
270
3127
6
11
188
2432
amoxicillin; oral, parenteral
J01CA04 [21602823]
1.1e+00
1.5e+00
2.7e+00
—
—
1.2e+00
1.0e+00
cases:45.26%
controls:21.33%
cases:24.77%
controls:6.77%
cases:4.28%
controls:0.31%
—
—
—
—
cases:16.25%
controls:5.65%
cases:40.21%
controls:19.07%
148
696
179
2567
81
221
246
3042
14
10
313
3253
—
—
45
177
232
2955
78
466
116
1977
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
7.8e-01
1.1e+00
1.9e+00
—
1.9e+00
1.2e+00
6.8e-01
cases:18.04%
controls:9.13%
cases:14.07%
controls:5.06%
cases:4.28%
controls:0.67%
—
—
cases:4.52%
controls:0.74%
cases:15.16%
controls:5.14%
cases:24.74%
controls:14.29%
59
298
268
2965
46
165
281
3098
14
22
313
3241
—
14
24
296
3232
42
161
235
2971
48
349
146
2094
Pharmacy visit
OMOP4822462 [581458]
8.7e-01
1.9e+00
1.5e+00
1.9e+00
9.0e-01
1.3e+00
6.0e-01
cases:97.55%
controls:94.36%
cases:97.86%
controls:86.82%
cases:83.18%
controls:51.27%
cases:13.15%
controls:2.30%
cases:71.61%
controls:50.68%
cases:96.03%
controls:87.20%
cases:97.42%
controls:95.42%
319
3079
8
184
320
2833
7
430
272
1673
55
1590
43
75
284
3188
222
1650
88
1606
266
2731
11
401
189
2331
5
112
Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection
21363-7 [3020565]
2.3e+00
—
1.0e+50
—
1.0e+50
2.6e+00
2.6e+00
cases:3.06%
controls:0.31%
—
—
cases:3.98%
controls:0.00%
—
—
cases:3.87%
controls:0.00%
cases:2.53%
controls:0.19%
cases:3.61%
controls:0.29%
10
10
317
3253
—
13
0
314
3263
—
12
0
298
3256
7
6
270
3126
7
7
187
2436
Laboratory Visit
OMOP4822461 [32036]
1.4e-01
4.0e-01
1.8e+00
3.7e+00
1.6e+00
3.4e-01
1.1e-01
cases:49.54%
controls:46.15%
cases:52.91%
controls:42.91%
cases:48.93%
controls:13.85%
cases:24.77%
controls:0.83%
cases:40.65%
controls:11.89%
cases:53.43%
controls:44.99%
cases:65.46%
controls:63.00%
162
1506
165
1757
173
1400
154
1863
160
452
167
2811
81
27
246
3236
126
387
184
2869
148
1409
129
1723
127
1539
67
904
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
1.3e+00
2.6e+00
—
—
—
2.5e+00
1.1e+00
cases:8.56%
controls:2.60%
cases:9.48%
controls:0.74%
—
—
—
—
—
—
cases:9.75%
controls:0.86%
cases:8.76%
controls:3.23%
28
85
299
3178
31
24
296
3239
—
—
—
27
27
250
3105
17
79
177
2364
Antithrombin actual/normal in Platelet poor plasma by Chromogenic method
27811-9 [3000515]
2.0e+00
—
—
—
—
2.9e+00
2.6e+00
cases:4.89%
controls:0.70%
—
—
—
—
—
—
—
—
cases:2.89%
controls:0.16%
cases:3.61%
controls:0.29%
16
23
311
3240
—
—
—
—
8
5
269
3127
7
7
187
2436
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
5.7e-01
1.1e+00
2.2e+00
—
2.4e+00
1.1e+00
4.9e-01
cases:26.30%
controls:16.86%
cases:20.18%
controls:8.03%
cases:10.09%
controls:1.20%
—
—
cases:9.35%
controls:0.89%
cases:21.30%
controls:8.01%
cases:29.90%
controls:20.75%
86
550
241
2713
66
262
261
3001
33
39
294
3224
—
29
29
281
3227
59
251
218
2881
58
507
136
1936
Aspergillus fumigatus IgE Ab [Units/volume] in Serum
6025-1 [3011951]
2.7e+00
—
1.0e+50
—
1.0e+50
1.0e+50
4.7e+00
cases:4.28%
controls:0.31%
—
—
cases:7.03%
controls:0.00%
—
—
cases:3.87%
controls:0.00%
cases:8.30%
controls:0.00%
cases:19.07%
controls:0.20%
14
10
313
3253
—
23
0
304
3263
—
12
0
298
3256
23
0
254
3132
37
5
157
2438
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
2.7e+00
2.0e+00
—
—
—
2.8e+00
1.4e+00
cases:5.81%
controls:0.43%
cases:3.06%
controls:0.43%
—
—
—
—
—
—
cases:4.33%
controls:0.29%
cases:2.58%
controls:0.65%
19
14
308
3249
10
14
317
3249
—
—
—
12
9
265
3123
5
16
189
2427
Bacteria identified in Sputum by Culture
6460-0 [3023419]
3.3e+00
—
—
—
—
—
4.1e+00
cases:7.65%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
cases:14.43%
controls:0.29%
25
10
302
3253
—
—
—
—
—
28
7
166
2436
aciclovir; oral, parenteral
J05AB01 [21603131]
1.0e+00
1.6e+00
2.3e+00
—
2.4e+00
1.2e+00
6.9e-01
cases:6.12%
controls:2.27%
cases:4.59%
controls:0.95%
cases:2.14%
controls:0.21%
—
—
cases:1.61%
controls:0.15%
cases:3.97%
controls:1.18%
cases:4.64%
controls:2.37%
20
74
307
3189
15
31
312
3232
7
7
320
3256
—
5
5
305
3251
11
37
266
3095
9
58
185
2385
Physiotherapist
Z3226 [2001311560]
1.3e+00
2.1e+00
—
1.0e+50
—
2.3e+00
1.6e+00
cases:7.65%
controls:2.27%
cases:4.89%
controls:0.61%
—
—
cases:2.75%
controls:0.00%
—
—
cases:5.42%
controls:0.57%
cases:7.73%
controls:1.64%
25
74
302
3189
16
20
311
3243
—
9
0
318
3263
—
15
18
262
3114
15
40
179
2403
Medical Oncology
90 [38004507]
1.0e+00
1.3e+00
1.4e+00
—
1.2e+00
1.3e+00
1.1e+00
cases:10.40%
controls:4.11%
cases:11.01%
controls:3.13%
cases:4.89%
controls:1.29%
—
—
cases:3.87%
controls:1.17%
cases:9.75%
controls:3.00%
cases:12.37%
controls:4.46%
34
134
293
3129
36
102
291
3161
16
42
311
3221
—
12
38
298
3218
27
94
250
3038
24
109
170
2334
Fever, unspecified
R50.9 [45582716]
1.8e+00
2.2e+00
—
—
—
1.8e+00
1.5e+00
cases:7.34%
controls:1.35%
cases:5.50%
controls:0.64%
—
—
—
—
—
—
cases:3.97%
controls:0.67%
cases:9.28%
controls:2.17%
24
44
303
3219
18
21
309
3242
—
—
—
11
21
266
3111
18
53
176
2390
valaciclovir; oral
J05AB11 [21603137]
1.3e+00
2.1e+00
—
—
—
2.5e+00
1.4e+00
cases:6.73%
controls:2.02%
cases:7.34%
controls:0.92%
—
—
—
—
—
—
cases:8.30%
controls:0.77%
cases:9.28%
controls:2.42%
22
66
305
3197
24
30
303
3233
—
—
—
23
24
254
3108
18
59
176
2384
Immunohistochemistry procedure
117617002 [4035726]
1.3e+00
2.3e+00
—
—
—
2.2e+00
1.4e+00
cases:6.42%
controls:1.90%
cases:4.59%
controls:0.49%
—
—
—
—
—
—
cases:4.33%
controls:0.48%
cases:5.15%
controls:1.31%
21
62
306
3201
15
16
312
3247
—
—
—
12
15
265
3117
10
32
184
2411
oxycodone; oral, parenteral
N02AA05 [21604260]
1.0e+00
1.8e+00
1.3e+00
—
2.3e+00
1.9e+00
1.3e+00
cases:4.28%
controls:1.59%
cases:5.20%
controls:0.92%
cases:1.83%
controls:0.52%
—
—
cases:2.58%
controls:0.28%
cases:6.86%
controls:1.12%
cases:9.28%
controls:2.78%
14
52
313
3211
17
30
310
3233
6
17
321
3246
—
8
9
302
3247
19
35
258
3097
18
68
176
2375
Gastroenterology
10 [38004455]
1.1e+00
1.3e+00
1.3e+00
—
2.0e+00
1.5e+00
1.1e+00
cases:15.60%
controls:5.64%
cases:8.26%
controls:2.30%
cases:1.53%
controls:0.43%
—
—
cases:3.23%
controls:0.43%
cases:8.66%
controls:1.98%
cases:15.98%
controls:5.94%
51
184
276
3079
27
75
300
3188
5
14
322
3249
—
10
14
300
3242
24
62
253
3070
31
145
163
2298
Thoracal epidural anesthesia
WX302 [2001310795]
1.6e+00
2.9e+00
—
—
—
2.6e+00
2.2e+00
cases:3.98%
controls:0.83%
cases:2.75%
controls:0.15%
—
—
—
—
—
—
cases:2.17%
controls:0.16%
cases:2.58%
controls:0.29%
13
27
314
3236
9
5
318
3258
—
—
—
6
5
271
3127
5
7
189
2436
erdosteine; oral
R05CB15 [21603394]
1.1e+00
2.0e+00
—
—
—
2.2e+00
1.9e+00
cases:8.87%
controls:3.10%
cases:10.09%
controls:1.50%
—
—
—
—
—
—
cases:11.19%
controls:1.44%
cases:21.65%
controls:4.09%
29
101
298
3162
33
49
294
3214
—
—
—
31
45
246
3087
42
100
152
2343
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
1.4e+00
1.6e+00
—
—
—
2.1e+00
2.0e+00
cases:4.28%
controls:1.04%
cases:2.75%
controls:0.58%
—
—
—
—
—
—
cases:2.89%
controls:0.35%
cases:6.70%
controls:0.98%
14
34
313
3229
9
19
318
3244
—
—
—
8
11
269
3121
13
24
181
2419
More than one and less than three hours
ZXE10 [2001311401]
5.6e-01
1.7e+00
—
—
2.7e+00
1.7e+00
9.7e-01
cases:10.70%
controls:6.41%
cases:6.12%
controls:1.13%
—
—
—
—
cases:2.26%
controls:0.15%
cases:5.42%
controls:1.02%
cases:9.79%
controls:3.97%
35
209
292
3054
20
37
307
3226
—
—
7
5
303
3251
15
32
262
3100
19
97
175
2346
INR in Blood by Coagulation assay
34714-6 [3032080]
4.7e-01
1.3e+00
1.7e+00
—
1.9e+00
1.3e+00
8.5e-01
cases:20.18%
controls:13.61%
cases:22.32%
controls:7.14%
cases:12.23%
controls:2.39%
—
—
cases:10.65%
controls:1.78%
cases:19.86%
controls:6.39%
cases:28.87%
controls:14.78%
66
444
261
2819
73
233
254
3030
40
78
287
3185
—
33
58
277
3198
55
200
222
2932
56
361
138
2082
X-ray examination of the lungs in one projection
GD1PA [2001303645]
1.4e+00
2.3e+00
—
1.0e+50
—
1.9e+00
1.5e+00
cases:5.20%
controls:1.32%
cases:4.28%
controls:0.46%
—
—
cases:2.45%
controls:0.00%
—
—
cases:3.61%
controls:0.57%
cases:6.19%
controls:1.51%
17
43
310
3220
14
15
313
3248
—
8
0
319
3263
—
10
18
267
3114
12
37
182
2406
Dyspnoea
R06.0 [45558449]
9.1e-01
1.4e+00
2.0e+00
—
—
1.6e+00
9.9e-01
cases:9.48%
controls:4.05%
cases:5.50%
controls:1.38%
cases:2.14%
controls:0.31%
—
—
—
—
cases:6.14%
controls:1.31%
cases:12.37%
controls:4.99%
31
132
296
3131
18
45
309
3218
7
10
320
3253
—
—
17
41
260
3091
24
122
170
2321
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
2.0e+00
—
—
—
—
2.4e+00
2.5e+00
cases:4.28%
controls:0.61%
—
—
—
—
—
—
—
—
cases:1.81%
controls:0.16%
cases:4.12%
controls:0.37%
14
20
313
3243
—
—
—
—
5
5
272
3127
8
9
186
2434
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
2.4e-01
1.1e+00
2.0e+00
—
2.6e+00
1.2e+00
4.9e-01
cases:14.07%
controls:11.40%
cases:12.84%
controls:4.66%
cases:5.20%
controls:0.77%
—
—
cases:5.81%
controls:0.46%
cases:13.36%
controls:4.50%
cases:21.65%
controls:14.53%
46
372
281
2891
42
152
285
3111
17
25
310
3238
—
18
15
292
3241
37
141
240
2991
42
355
152
2088
Pneumonia
R81 [2002000949]
2.3e+00
2.2e+00
—
—
—
—
2.3e+00
cases:3.98%
controls:0.43%
cases:2.75%
controls:0.31%
—
—
—
—
—
—
—
—
cases:3.61%
controls:0.37%
13
14
314
3249
9
10
318
3253
—
—
—
—
7
9
187
2434
General anesthesia, balanced
WX408 [2001310808]
9.3e-01
1.9e+00
—
—
—
2.3e+00
1.6e+00
cases:9.79%
controls:4.11%
cases:5.81%
controls:0.92%
—
—
—
—
—
—
cases:5.05%
controls:0.51%
cases:10.31%
controls:2.29%
32
134
295
3129
19
30
308
3233
—
—
—
14
16
263
3116
20
56
174
2387
Repeated or continuing anesthesia shots throug a catheter
WX602 [2001310813]
1.6e+00
2.8e+00
—
—
—
—
2.3e+00
cases:3.98%
controls:0.80%
cases:2.45%
controls:0.15%
—
—
—
—
—
—
—
—
cases:3.61%
controls:0.37%
13
26
314
3237
8
5
319
3258
—
—
—
—
7
9
187
2434
magnesium hydroxide; oral
G04BX01 [21602658]
1.8e+00
2.3e+00
—
—
—
2.6e+00
1.4e+00
cases:2.45%
controls:0.40%
cases:2.75%
controls:0.28%
—
—
—
—
—
—
cases:2.89%
controls:0.22%
cases:3.09%
controls:0.78%
8
13
319
3250
9
9
318
3254
—
—
—
8
7
269
3125
6
19
188
2424
magnesium hydroxide; oral
A02AA04 [21600052]
1.8e+00
2.3e+00
—
—
—
2.6e+00
1.4e+00
cases:2.45%
controls:0.40%
cases:2.75%
controls:0.28%
—
—
—
—
—
—
cases:2.89%
controls:0.22%
cases:3.09%
controls:0.78%
8
13
319
3250
9
9
318
3254
—
—
—
8
7
269
3125
6
19
188
2424
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
1.5e+00
1.7e+00
—
—
—
1.9e+00
1.7e+00
cases:7.34%
controls:1.69%
cases:3.98%
controls:0.77%
—
—
—
—
—
—
cases:3.61%
controls:0.57%
cases:8.76%
controls:1.80%
24
55
303
3208
13
25
314
3238
—
—
—
10
18
267
3114
17
44
177
2399
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
1.3e+00
1.8e+00
2.3e+00
—
—
1.3e+00
1.2e+00
cases:7.95%
controls:2.21%
cases:5.81%
controls:0.98%
cases:1.83%
controls:0.18%
—
—
—
—
cases:2.53%
controls:0.70%
cases:6.70%
controls:2.09%
26
72
301
3191
19
32
308
3231
6
6
321
3257
—
—
7
22
270
3110
13
51
181
2392
Interstitial pulmonary disease, unspecified
J84.9 [45543277]
2.3e+00
2.0e+00
—
—
—
2.3e+00
—
cases:2.75%
controls:0.28%
cases:1.83%
controls:0.25%
—
—
—
—
—
—
cases:2.17%
controls:0.22%
—
—
9
9
318
3254
6
8
321
3255
—
—
—
6
7
271
3125
—
ECG with 12 standard connections
XF400 [2001303368]
1.1e+00
2.1e+00
—
—
—
2.0e+00
1.4e+00
cases:6.73%
controls:2.24%
cases:4.28%
controls:0.52%
—
—
—
—
—
—
cases:2.53%
controls:0.35%
cases:6.19%
controls:1.68%
22
73
305
3190
14
17
313
3246
—
—
—
7
11
270
3121
12
41
182
2402
Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection
23826-1 [3012477]
2.2e+00
—
1.0e+50
—
1.0e+50
2.2e+00
2.2e+00
cases:3.06%
controls:0.34%
—
—
cases:3.98%
controls:0.00%
—
—
cases:4.52%
controls:0.00%
cases:2.53%
controls:0.29%
cases:3.61%
controls:0.41%
10
11
317
3252
—
13
0
314
3263
—
14
0
296
3256
7
9
270
3123
7
10
187
2433
theophylline; oral, parenteral, rectal
R03DA04 [21603332]
2.4e+00
2.2e+00
-1.0e+50
—
—
1.4e+00
2.1e+00
cases:5.50%
controls:0.55%
cases:3.67%
controls:0.43%
cases:0.00%
controls:0.15%
—
—
—
—
cases:1.81%
controls:0.45%
cases:5.67%
controls:0.74%
18
18
309
3245
12
14
315
3249
0
5
327
3258
—
—
5
14
272
3118
11
18
183
2425
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
1.0e+00
2.0e+00
—
—
—
2.0e+00
1.5e+00
cases:9.48%
controls:3.56%
cases:8.56%
controls:1.23%
—
—
—
—
—
—
cases:7.22%
controls:1.02%
cases:14.43%
controls:3.64%
31
116
296
3147
28
40
299
3223
—
—
—
20
32
257
3100
28
89
166
2354
ipratropium bromide; inhalant
R03BB01 [21603293]
1.8e+00
2.6e+00
—
—
—
—
2.2e+00
cases:2.45%
controls:0.43%
cases:2.45%
controls:0.18%
—
—
—
—
—
—
—
—
cases:4.64%
controls:0.53%
8
14
319
3249
8
6
319
3257
—
—
—
—
9
13
185
2430
clarithromycin; oral, parenteral
J01FA09 [21602977]
1.2e+00
2.4e+00
—
—
—
1.7e+00
1.3e+00
cases:10.40%
controls:3.43%
cases:4.28%
controls:0.40%
—
—
—
—
—
—
cases:2.89%
controls:0.54%
cases:5.67%
controls:1.64%
34
112
293
3151
14
13
313
3250
—
—
—
8
17
269
3115
11
40
183
2403
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
1.4e+00
3.2e+00
—
—
—
2.3e+00
1.9e+00
cases:3.67%
controls:0.89%
cases:4.28%
controls:0.18%
—
—
—
—
—
—
cases:1.81%
controls:0.19%
cases:4.64%
controls:0.70%
12
29
315
3234
14
6
313
3257
—
—
—
5
6
272
3126
9
17
185
2426
mycophenolic acid; oral, parenteral
L04AA06 [21603896]
1.8e+00
2.4e+00
—
—
—
2.3e+00
2.0e+00
cases:2.45%
controls:0.40%
cases:4.28%
controls:0.40%
—
—
—
—
—
—
cases:3.97%
controls:0.42%
cases:2.58%
controls:0.37%
8
13
319
3250
14
13
313
3250
—
—
—
11
13
266
3119
5
9
189
2434
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
1.0e+00
1.3e+00
1.7e+00
—
1.6e+00
1.2e+00
1.3e+00
cases:15.90%
controls:6.50%
cases:9.48%
controls:2.73%
cases:3.06%
controls:0.58%
—
—
cases:2.26%
controls:0.46%
cases:8.66%
controls:2.68%
cases:22.16%
controls:7.33%
52
212
275
3051
31
89
296
3174
10
19
317
3244
—
7
15
303
3241
24
84
253
3048
43
179
151
2264
fluticasone furoate
R03BA09 [45893496]
1.8e+00
1.5e+00
1.6e+00
—
—
1.6e+00
1.5e+00
cases:13.46%
controls:2.42%
cases:5.81%
controls:1.32%
cases:1.53%
controls:0.31%
—
—
—
—
cases:5.05%
controls:1.02%
cases:8.76%
controls:2.13%
44
79
283
3184
19
43
308
3220
5
10
322
3253
—
—
14
32
263
3100
17
52
177
2391
Extensive high resolution CT examination of lungs
GD1ED [2001303637]
2.9e+00
—
1.0e+50
1.0e+50
—
—
3.6e+00
cases:5.20%
controls:0.31%
—
—
cases:1.53%
controls:0.00%
cases:2.45%
controls:0.00%
—
—
—
—
cases:8.25%
controls:0.25%
17
10
310
3253
—
5
0
322
3263
8
0
319
3263
—
—
16
6
178
2437
Human bocavirus DNA [Presence] in Specimen by NAA with probe detection
62424-7 [40765161]
2.6e+00
—
1.0e+50
—
1.0e+50
—
3.8e+00
cases:3.36%
controls:0.25%
—
—
cases:3.98%
controls:0.00%
—
—
cases:5.48%
controls:0.00%
—
—
cases:8.25%
controls:0.20%
11
8
316
3255
—
13
0
314
3263
—
17
0
293
3256
—
16
5
178
2438
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
7.0e-01
1.1e+00
2.2e+00
—
2.4e+00
7.8e-01
4.6e-01
cases:12.23%
controls:6.50%
cases:9.79%
controls:3.56%
cases:5.50%
controls:0.61%
—
—
cases:2.90%
controls:0.28%
cases:7.94%
controls:3.80%
cases:14.95%
controls:9.99%
40
212
287
3051
32
116
295
3147
18
20
309
3243
—
9
9
301
3247
22
119
255
3013
29
244
165
2199
Acute bronchitis, unspecified
J20.9 [45562445]
9.7e-01
1.8e+00
—
—
—
1.9e+00
1.8e+00
cases:7.03%
controls:2.79%
cases:4.89%
controls:0.86%
—
—
—
—
—
—
cases:3.25%
controls:0.51%
cases:14.95%
controls:2.95%
23
91
304
3172
16
28
311
3235
—
—
—
9
16
268
3116
29
72
165
2371
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
9.8e-01
2.0e+00
—
—
—
2.5e+00
1.9e+00
cases:3.06%
controls:1.16%
cases:2.75%
controls:0.37%
—
—
—
—
—
—
cases:4.69%
controls:0.42%
cases:7.22%
controls:1.19%
10
38
317
3225
9
12
318
3251
—
—
—
13
13
264
3119
14
29
180
2414
Medical doctor
Z2221 [2001311556]
9.0e-01
2.0e+00
—
1.0e+50
—
1.9e+00
1.6e+00
cases:10.70%
controls:4.66%
cases:9.17%
controls:1.41%
—
—
cases:3.36%
controls:0.00%
—
—
cases:6.86%
controls:1.09%
cases:12.89%
controls:2.87%
35
152
292
3111
30
46
297
3217
—
11
0
316
3263
—
19
34
258
3098
25
70
169
2373
Otitis externa, unspecified
H60.9 [45605727]
1.6e+00
2.5e+00
—
—
—
2.3e+00
1.4e+00
cases:3.67%
controls:0.80%
cases:3.98%
controls:0.34%
—
—
—
—
—
—
cases:3.97%
controls:0.42%
cases:4.12%
controls:1.06%
12
26
315
3237
13
11
314
3252
—
—
—
11
13
266
3119
8
26
186
2417
SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
94759-8 [586526]
1.4e+00
2.4e+00
—
—
—
2.6e+00
1.3e+00
cases:3.36%
controls:0.89%
cases:3.06%
controls:0.28%
—
—
—
—
—
—
cases:3.61%
controls:0.29%
cases:4.64%
controls:1.27%
11
29
316
3234
10
9
317
3254
—
—
—
10
9
267
3123
9
31
185
2412
12 lead EKG panel
34534-8 [3044889]
3.3e-01
8.3e-01
2.0e+00
—
2.6e+00
9.4e-01
3.1e-01
cases:27.83%
controls:21.64%
cases:21.71%
controls:10.82%
cases:10.09%
controls:1.50%
—
—
cases:12.58%
controls:1.11%
cases:22.74%
controls:10.31%
cases:33.51%
controls:26.98%
91
706
236
2557
71
353
256
2910
33
49
294
3214
—
39
36
271
3220
63
323
214
2809
65
659
129
1784
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
5.1e-01
8.5e-01
1.7e+00
1.0e+50
2.2e+00
1.4e+00
6.7e-01
cases:11.93%
controls:7.54%
cases:7.34%
controls:3.28%
cases:2.75%
controls:0.49%
cases:1.53%
controls:0.00%
cases:3.55%
controls:0.40%
cases:10.47%
controls:2.68%
cases:15.98%
controls:8.88%
39
246
288
3017
24
107
303
3156
9
16
318
3247
5
0
322
3263
11
13
299
3243
29
84
248
3048
31
217
163
2226
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
1.1e+00
2.1e+00
—
1.0e+50
—
1.9e+00
1.2e+00
cases:8.26%
controls:3.00%
cases:8.26%
controls:1.13%
—
—
cases:1.83%
controls:0.00%
—
—
cases:7.94%
controls:1.28%
cases:11.34%
controls:3.64%
27
98
300
3165
27
37
300
3226
—
6
0
321
3263
—
22
40
255
3092
22
89
172
2354
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.1e+00
1.8e+00
—
—
2.4e+00
1.2e+00
9.9e-01
cases:12.84%
controls:4.66%
cases:7.34%
controls:1.35%
—
—
—
—
cases:1.94%
controls:0.18%
cases:3.61%
controls:1.15%
cases:10.31%
controls:4.09%
42
152
285
3111
24
44
303
3219
—
—
6
6
304
3250
10
36
267
3096
20
100
174
2343
dexamethasone and antiinfectives
S02CA06 [21605178]
1.3e+00
2.3e+00
—
—
—
2.1e+00
1.8e+00
cases:2.14%
controls:0.58%
cases:3.06%
controls:0.31%
—
—
—
—
—
—
cases:3.25%
controls:0.42%
cases:8.76%
controls:1.56%
7
19
320
3244
10
10
317
3253
—
—
—
9
13
268
3119
17
38
177
2405
Thorax extensive CT-examination
GD1BD [2001303621]
2.8e+00
—
1.0e+50
1.0e+50
1.0e+50
—
3.4e+00
cases:7.03%
controls:0.46%
—
—
cases:2.45%
controls:0.00%
cases:2.75%
controls:0.00%
cases:1.94%
controls:0.00%
—
—
cases:7.73%
controls:0.29%
23
15
304
3248
—
8
0
319
3263
9
0
318
3263
6
0
304
3256
—
15
7
179
2436
Paranasal sinuses X-ray examination without contrast
DM1AA [2001301740]
3.1e+00
—
—
1.0e+50
—
1.0e+50
3.0e+00
cases:5.20%
controls:0.25%
—
—
—
—
cases:2.45%
controls:0.00%
—
—
cases:3.97%
controls:0.00%
cases:5.67%
controls:0.29%
17
8
310
3255
—
—
8
0
319
3263
—
11
0
266
3132
11
7
183
2436
azithromycin; oral, parenteral
J01FA10 [21602978]
1.4e+00
1.7e+00
—
—
—
1.7e+00
1.3e+00
cases:20.18%
controls:5.82%
cases:9.17%
controls:1.75%
—
—
—
—
—
—
cases:7.22%
controls:1.37%
cases:14.43%
controls:4.58%
66
190
261
3073
30
57
297
3206
—
—
—
20
43
257
3089
28
112
166
2331
Monitored bed care
WX892 [2001310850]
1.1e+00
2.0e+00
—
—
—
2.2e+00
1.9e+00
cases:2.75%
controls:0.92%
cases:2.75%
controls:0.37%
—
—
—
—
—
—
cases:2.17%
controls:0.26%
cases:4.12%
controls:0.65%
9
30
318
3233
9
12
318
3251
—
—
—
6
8
271
3124
8
16
186
2427
CD4 cells/Lymphocytes in Specimen
80223-1 [21494815]
2.8e+00
—
—
—
1.0e+50
—
3.3e+00
cases:2.45%
controls:0.15%
—
—
—
—
—
—
cases:1.61%
controls:0.00%
—
—
cases:5.15%
controls:0.20%
8
5
319
3258
—
—
—
5
0
305
3256
—
10
5
184
2438
Blood transfusion
WW500 [2001310603]
2.9e+00
1.0e+50
1.0e+50
—
1.0e+50
3.2e+00
—
cases:3.67%
controls:0.21%
cases:5.50%
controls:0.00%
cases:3.98%
controls:0.00%
—
—
cases:2.58%
controls:0.00%
cases:3.61%
controls:0.16%
—
—
12
7
315
3256
18
0
309
3263
13
0
314
3263
—
8
0
302
3256
10
5
267
3127
—
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2.8e-01
9.4e-01
2.0e+00
—
2.1e+00
9.4e-01
4.3e-01
cases:22.02%
controls:17.56%
cases:17.13%
controls:7.48%
cases:8.26%
controls:1.16%
—
—
cases:7.74%
controls:1.01%
cases:16.97%
controls:7.38%
cases:30.41%
controls:22.14%
72
573
255
2690
56
244
271
3019
27
38
300
3225
—
24
33
286
3223
47
231
230
2901
59
541
135
1902
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
6.3e-01
2.6e+00
—
—
—
1.9e+00
1.5e+00
cases:2.45%
controls:1.32%
cases:3.98%
controls:0.31%
—
—
—
—
—
—
cases:3.25%
controls:0.48%
cases:5.15%
controls:1.23%
8
43
319
3220
13
10
314
3253
—
—
—
9
15
268
3117
10
30
184
2413
Other specified special examinations
Z01.8 [45581003]
9.6e-01
1.7e+00
—
—
—
1.8e+00
1.5e+00
cases:8.56%
controls:3.46%
cases:3.98%
controls:0.74%
—
—
—
—
—
—
cases:6.14%
controls:1.05%
cases:12.89%
controls:3.15%
28
113
299
3150
13
24
314
3239
—
—
—
17
33
260
3099
25
77
169
2366
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
D38.1 [45605357]
2.5e+00
3.4e+00
—
—
1.0e+50
—
—
cases:3.36%
controls:0.28%
cases:4.59%
controls:0.15%
—
—
—
—
cases:1.61%
controls:0.00%
—
—
—
—
11
9
316
3254
15
5
312
3258
—
—
5
0
305
3256
—
—
Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
95941-1 [36031861]
1.3e+00
2.0e+00
—
—
—
2.5e+00
1.4e+00
cases:1.83%
controls:0.49%
cases:2.75%
controls:0.37%
—
—
—
—
—
—
cases:5.05%
controls:0.42%
cases:5.15%
controls:1.35%
6
16
321
3247
9
12
318
3251
—
—
—
14
13
263
3119
10
33
184
2410
clindamycin; oral, parenteral
J01FF01 [21602985]
9.1e-01
1.6e+00
—
—
—
1.8e+00
1.6e+00
cases:8.26%
controls:3.49%
cases:5.20%
controls:1.04%
—
—
—
—
—
—
cases:5.05%
controls:0.86%
cases:12.37%
controls:2.82%
27
114
300
3149
17
34
310
3229
—
—
—
14
27
263
3105
24
69
170
2374
Procalcitonin [Mass/volume] in Serum or Plasma
33959-8 [3046279]
1.6e+00
—
—
—
—
2.3e+00
2.1e+00
cases:2.75%
controls:0.58%
—
—
—
—
—
—
—
—
cases:3.61%
controls:0.38%
cases:7.22%
controls:0.94%
9
19
318
3244
—
—
—
—
10
12
267
3120
14
23
180
2420
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
4.0e-01
8.4e-01
2.0e+00
—
2.2e+00
9.4e-01
5.2e-01
cases:25.69%
controls:18.82%
cases:19.57%
controls:9.47%
cases:10.09%
controls:1.53%
—
—
cases:10.97%
controls:1.41%
cases:20.22%
controls:9.04%
cases:33.51%
controls:23.00%
84
614
243
2649
64
309
263
2954
33
50
294
3213
—
34
46
276
3210
56
283
221
2849
65
562
129
1881
EKG study
11524-6 [3013512]
4.0e-01
9.6e-01
2.3e+00
—
2.7e+00
7.1e-01
4.3e-01
cases:12.23%
controls:8.52%
cases:10.40%
controls:4.26%
cases:5.81%
controls:0.64%
—
—
cases:5.48%
controls:0.40%
cases:9.03%
controls:4.63%
cases:19.07%
controls:13.34%
40
278
287
2985
34
139
293
3124
19
21
308
3242
—
17
13
293
3243
25
145
252
2987
37
326
157
2117
fenoterol and ipratropium bromide
R03AL01 [43534843]
2.1e+00
2.0e+00
—
—
—
1.6e+00
1.8e+00
cases:4.28%
controls:0.52%
cases:2.75%
controls:0.40%
—
—
—
—
—
—
cases:2.53%
controls:0.51%
cases:6.19%
controls:1.11%
14
17
313
3246
9
13
318
3250
—
—
—
7
16
270
3116
12
27
182
2416
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
7.4e-01
1.1e+00
2.1e+00
—
2.6e+00
6.6e-01
6.8e-01
cases:6.73%
controls:3.34%
cases:7.95%
controls:2.82%
cases:2.75%
controls:0.34%
—
—
cases:2.90%
controls:0.21%
cases:5.78%
controls:3.07%
cases:14.95%
controls:8.15%
22
109
305
3154
26
92
301
3171
9
11
318
3252
—
9
7
301
3249
16
96
261
3036
29
199
165
2244
Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
3216-9 [3020427]
1.4e+00
3.2e+00
—
—
—
2.6e+00
1.7e+00
cases:2.75%
controls:0.67%
cases:3.67%
controls:0.15%
—
—
—
—
—
—
cases:3.97%
controls:0.32%
cases:2.58%
controls:0.49%
9
22
318
3241
12
5
315
3258
—
—
—
11
10
266
3122
5
12
189
2431
Parainfluenza type 3 nucleic acid detection
222361000000104 [44790049]
2.8e+00
—
1.0e+50
—
1.0e+50
—
2.9e+00
cases:2.45%
controls:0.15%
—
—
cases:3.06%
controls:0.00%
—
—
cases:5.16%
controls:0.00%
—
—
cases:5.15%
controls:0.29%
8
5
319
3258
—
10
0
317
3263
—
16
0
294
3256
—
10
7
184
2436
Parainfluenza type 2 nucleic acid detection
222351000000102 [44790048]
2.8e+00
—
1.0e+50
—
1.0e+50
—
2.9e+00
cases:2.45%
controls:0.15%
—
—
cases:3.06%
controls:0.00%
—
—
cases:5.16%
controls:0.00%
—
—
cases:5.15%
controls:0.29%
8
5
319
3258
—
10
0
317
3263
—
16
0
294
3256
—
10
7
184
2436
Parainfluenza type 4 nucleic acid detection
810871000000102 [44806118]
2.8e+00
—
1.0e+50
—
1.0e+50
—
2.9e+00
cases:2.45%
controls:0.15%
—
—
cases:3.06%
controls:0.00%
—
—
cases:5.16%
controls:0.00%
—
—
cases:5.15%
controls:0.29%
8
5
319
3258
—
10
0
317
3263
—
16
0
294
3256
—
10
7
184
2436
Parainfluenza type 1 nucleic acid detection
222341000000100 [44790047]
2.8e+00
—
1.0e+50
—
1.0e+50
—
2.9e+00
cases:2.45%
controls:0.15%
—
—
cases:3.06%
controls:0.00%
—
—
cases:5.16%
controls:0.00%
—
—
cases:5.15%
controls:0.29%
8
5
319
3258
—
10
0
317
3263
—
16
0
294
3256
—
10
7
184
2436
alendronic acid; oral
M05BA04 [21604152]
8.1e-01
1.7e+00
—
—
—
2.1e+00
1.9e+00
cases:2.45%
controls:1.10%
cases:3.36%
controls:0.64%
—
—
—
—
—
—
cases:5.42%
controls:0.70%
cases:9.28%
controls:1.43%
8
36
319
3227
11
21
316
3242
—
—
—
15
22
262
3110
18
35
176
2408
Chronic lymphocytic leukaemia of B-cell type
C91.1 [45600564]
2.8e+00
2.9e+00
—
1.0e+50
—
—
—
cases:3.36%
controls:0.21%
cases:3.36%
controls:0.18%
—
—
cases:3.06%
controls:0.00%
—
—
—
—
—
—
11
7
316
3256
11
6
316
3257
—
10
0
317
3263
—
—
—
Mycobacterium sp identified in Specimen by Organism specific culture
543-9 [3005702]
2.6e+00
—
1.0e+50
—
—
—
3.1e+00
cases:6.42%
controls:0.52%
—
—
cases:7.03%
controls:0.00%
—
—
—
—
—
—
cases:8.76%
controls:0.41%
21
17
306
3246
—
23
0
304
3263
—
—
—
17
10
177
2433
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
3.2e+00
—
1.0e+50
—
1.0e+50
—
2.5e+00
cases:4.89%
controls:0.21%
—
—
cases:4.59%
controls:0.00%
—
—
cases:5.81%
controls:0.00%
—
—
cases:7.22%
controls:0.61%
16
7
311
3256
—
15
0
312
3263
—
18
0
292
3256
—
14
15
180
2428
cefalexin; oral
J01DB01 [21602870]
7.7e-01
1.2e+00
1.6e+00
—
7.5e-01
1.0e+00
1.0e+00
cases:47.40%
controls:29.48%
cases:22.94%
controls:8.21%
cases:5.20%
controls:1.07%
—
—
cases:2.26%
controls:1.07%
cases:20.22%
controls:8.30%
cases:49.48%
controls:25.71%
155
962
172
2301
75
268
252
2995
17
35
310
3228
—
7
35
303
3221
56
260
221
2872
96
628
98
1815
One hour or less
ZXE00 [2001311394]
8.8e-01
1.7e+00
—
—
—
1.8e+00
1.3e+00
cases:14.07%
controls:6.34%
cases:7.95%
controls:1.59%
—
—
—
—
—
—
cases:6.86%
controls:1.25%
cases:13.92%
controls:4.13%
46
207
281
3056
26
52
301
3211
—
—
—
19
39
258
3093
27
101
167
2342
Mycobacterium sp identified in Specimen
40699-1 [3042631]
2.3e+00
—
1.0e+50
—
—
—
3.3e+00
cases:3.67%
controls:0.37%
—
—
cases:2.75%
controls:0.00%
—
—
—
—
—
—
cases:6.19%
controls:0.25%
12
12
315
3251
—
9
0
318
3263
—
—
—
12
6
182
2437
Dentistry
C5 [903277]
1.1e+00
2.4e+00
—
—
—
2.1e+00
1.1e+00
cases:5.20%
controls:1.81%
cases:5.20%
controls:0.49%
—
—
—
—
—
—
cases:4.33%
controls:0.54%
cases:5.67%
controls:1.88%
17
59
310
3204
17
16
310
3247
—
—
—
12
17
265
3115
11
46
183
2397
Cathetrisation of vein
TPH04 [2001309597]
8.1e-01
1.9e+00
1.9e+00
—
—
1.9e+00
1.0e+00
cases:7.95%
controls:3.71%
cases:7.65%
controls:1.26%
cases:1.83%
controls:0.28%
—
—
—
—
cases:7.58%
controls:1.25%
cases:9.28%
controls:3.52%
26
121
301
3142
25
41
302
3222
6
9
321
3254
—
—
21
39
256
3093
18
86
176
2357
Mixed asthma
J45.8 [45548118]
3.0e+00
—
—
—
—
—
2.6e+00
cases:3.06%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
cases:3.09%
controls:0.25%
10
5
317
3258
—
—
—
—
—
6
6
188
2437
Acute maxillary sinusitis
J01.0 [45601112]
9.5e-01
1.8e+00
—
—
1.0e+50
1.3e+00
1.5e+00
cases:7.95%
controls:3.22%
cases:5.50%
controls:0.98%
—
—
—
—
cases:2.90%
controls:0.00%
cases:3.97%
controls:1.09%
cases:11.34%
controls:2.70%
26
105
301
3158
18
32
309
3231
—
—
9
0
301
3256
11
34
266
3098
22
66
172
2377
Respiratory and circulatory monitoring
WX700 [2001310817]
8.6e-01
1.8e+00
—
—
—
1.6e+00
1.3e+00
cases:6.73%
controls:2.97%
cases:5.50%
controls:0.98%
—
—
—
—
—
—
cases:3.25%
controls:0.67%
cases:8.25%
controls:2.29%
22
97
305
3166
18
32
309
3231
—
—
—
9
21
268
3111
16
56
178
2387
formoterol, glycopyrronium bromide and beclometasone
R03AL09 [1502099]
—
2.0e+00
—
—
—
1.7e+00
1.8e+00
—
—
cases:2.45%
controls:0.34%
—
—
—
—
—
—
cases:3.25%
controls:0.61%
cases:4.12%
controls:0.70%
—
8
11
319
3252
—
—
—
9
19
268
3113
8
17
186
2426
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
3.1e-01
1.7e+00
—
—
—
2.4e+00
1.4e+00
cases:1.83%
controls:1.35%
cases:2.75%
controls:0.52%
—
—
—
—
—
—
cases:3.61%
controls:0.35%
cases:5.67%
controls:1.47%
6
44
321
3219
9
17
318
3246
—
—
—
10
11
267
3121
11
36
183
2407
mometasone; nasal
R01AD09 [21605051]
7.0e-01
1.3e+00
1.5e+00
—
—
1.1e+00
8.3e-01
cases:15.90%
controls:8.55%
cases:12.23%
controls:3.62%
cases:3.06%
controls:0.67%
—
—
—
—
cases:9.03%
controls:3.35%
cases:13.92%
controls:6.59%
52
279
275
2984
40
118
287
3145
10
22
317
3241
—
—
25
105
252
3027
27
161
167
2282
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
3.1e-01
1.8e+00
—
—
—
2.2e+00
1.4e+00
cases:1.83%
controls:1.35%
cases:2.75%
controls:0.46%
—
—
—
—
—
—
cases:3.61%
controls:0.42%
cases:5.67%
controls:1.47%
6
44
321
3219
9
15
318
3248
—
—
—
10
13
267
3119
11
36
183
2407
Body CT examination
JN4AD [2001310897]
1.4e+00
1.6e+00
2.3e+00
1.0e+50
—
1.0e+00
1.3e+00
cases:3.67%
controls:0.89%
cases:4.59%
controls:0.95%
cases:1.83%
controls:0.18%
cases:2.45%
controls:0.00%
—
—
cases:2.89%
controls:1.09%
cases:5.15%
controls:1.51%
12
29
315
3234
15
31
312
3232
6
6
321
3257
8
0
319
3263
—
8
34
269
3098
10
37
184
2406
Clinic/Center
261Q00000X [38004207]
1.4e+00
2.3e+00
—
—
—
3.0e+00
1.6e+00
cases:2.14%
controls:0.52%
cases:2.45%
controls:0.25%
—
—
—
—
—
—
cases:3.25%
controls:0.16%
cases:2.58%
controls:0.53%
7
17
320
3246
8
8
319
3255
—
—
—
9
5
268
3127
5
13
189
2430
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
3.6e-01
7.2e-01
2.3e+00
—
1.7e+00
6.5e-01
2.4e-01
cases:15.60%
controls:11.37%
cases:11.62%
controls:6.01%
cases:6.73%
controls:0.74%
—
—
cases:4.84%
controls:0.95%
cases:13.00%
controls:7.25%
cases:22.16%
controls:18.30%
51
371
276
2892
38
196
289
3067
22
24
305
3239
—
15
31
295
3225
36
227
241
2905
43
447
151
1996
Base excess in Arterial blood by calculation
1925-7 [3003396]
7.9e-01
2.0e+00
—
—
—
2.1e+00
1.2e+00
cases:5.81%
controls:2.73%
cases:6.42%
controls:0.92%
—
—
—
—
—
—
cases:6.50%
controls:0.86%
cases:8.76%
controls:2.78%
19
89
308
3174
21
30
306
3233
—
—
—
18
27
259
3105
17
68
177
2375
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
6.3e-01
1.4e+00
1.8e+00
—
—
1.1e+00
1.0e+00
cases:7.03%
controls:3.86%
cases:7.65%
controls:2.08%
cases:2.14%
controls:0.37%
—
—
—
—
cases:5.42%
controls:1.85%
cases:11.34%
controls:4.42%
23
126
304
3137
25
68
302
3195
7
12
320
3251
—
—
15
58
262
3074
22
108
172
2335
Norovirus RNA [Presence] in Stool by NAA with probe detection
7974-9 [3008909]
1.3e+00
2.9e+00
—
—
—
—
2.3e+00
cases:1.83%
controls:0.52%
cases:2.75%
controls:0.15%
—
—
—
—
—
—
—
—
cases:4.12%
controls:0.41%
6
17
321
3246
9
5
318
3258
—
—
—
—
8
10
186
2433
Leukocyte morphology finding [Identifier] in Blood
11156-7 [3008757]
2.8e+00
—
—
—
—
—
2.4e+00
cases:2.45%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
cases:3.61%
controls:0.33%
8
5
319
3258
—
—
—
—
—
7
8
187
2435
pH of Arterial blood
2744-1 [3019977]
7.1e-01
2.0e+00
—
—
—
2.0e+00
1.2e+00
cases:5.50%
controls:2.79%
cases:6.42%
controls:0.92%
—
—
—
—
—
—
cases:6.14%
controls:0.86%
cases:8.76%
controls:2.82%
18
91
309
3172
21
30
306
3233
—
—
—
17
27
260
3105
17
69
177
2374
Spirometry study
18759-1 [3000492]
1.4e+00
2.6e+00
—
—
—
1.2e+00
1.2e+00
cases:7.34%
controls:1.93%
cases:5.20%
controls:0.40%
—
—
—
—
—
—
cases:2.53%
controls:0.80%
cases:6.70%
controls:2.13%
24
63
303
3200
17
13
310
3250
—
—
—
7
25
270
3107
13
52
181
2391
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
5.0e-01
8.3e-01
1.5e+00
—
2.2e+00
5.0e-01
6.3e-01
cases:14.68%
controls:9.44%
cases:10.70%
controls:4.96%
cases:2.75%
controls:0.61%
—
—
cases:2.90%
controls:0.34%
cases:8.30%
controls:5.20%
cases:24.23%
controls:14.49%
48
308
279
2955
35
162
292
3101
9
20
318
3243
—
9
11
301
3245
23
163
254
2969
47
354
147
2089
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.2e+00
1.4e+00
—
—
—
1.3e+00
1.3e+00
cases:9.79%
controls:3.25%
cases:6.73%
controls:1.75%
—
—
—
—
—
—
cases:4.69%
controls:1.31%
cases:10.31%
controls:3.11%
32
106
295
3157
22
57
305
3206
—
—
—
13
41
264
3091
20
76
174
2367
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
3.7e-01
6.9e-01
2.2e+00
—
1.6e+00
6.6e-01
2.4e-01
cases:16.21%
controls:11.83%
cases:11.62%
controls:6.16%
cases:6.73%
controls:0.80%
—
—
cases:4.84%
controls:1.01%
cases:13.36%
controls:7.38%
cases:22.68%
controls:18.71%
53
386
274
2877
38
201
289
3062
22
26
305
3237
—
15
33
295
3223
37
231
240
2901
44
457
150
1986
pH of Venous blood
2746-6 [3012544]
1.1e+00
1.4e+00
1.9e+00
—
2.6e+00
1.1e+00
7.8e-01
cases:5.81%
controls:1.93%
cases:4.28%
controls:1.13%
cases:1.83%
controls:0.28%
—
—
cases:2.90%
controls:0.21%
cases:2.89%
controls:0.99%
cases:6.70%
controls:3.19%
19
63
308
3200
14
37
313
3226
6
9
321
3254
—
9
7
301
3249
8
31
269
3101
13
78
181
2365
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
4.9e-01
8.0e-01
1.4e+00
—
2.1e+00
1.2e+00
1.0e+00
cases:13.76%
controls:8.92%
cases:9.79%
controls:4.66%
cases:2.14%
controls:0.55%
—
—
cases:3.23%
controls:0.40%
cases:13.36%
controls:4.41%
cases:27.32%
controls:12.08%
45
291
282
2972
32
152
295
3111
7
18
320
3245
—
10
13
300
3243
37
138
240
2994
53
295
141
2148
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
7.8e-01
1.9e+00
—
—
—
2.0e+00
1.2e+00
cases:5.81%
controls:2.76%
cases:5.81%
controls:0.89%
—
—
—
—
—
—
cases:6.14%
controls:0.86%
cases:8.76%
controls:2.87%
19
90
308
3173
19
29
308
3234
—
—
—
17
27
260
3105
17
70
177
2373
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
7.8e-01
1.9e+00
—
—
—
2.0e+00
1.2e+00
cases:5.81%
controls:2.76%
cases:5.81%
controls:0.89%
—
—
—
—
—
—
cases:6.14%
controls:0.86%
cases:8.76%
controls:2.87%
19
90
308
3173
19
29
308
3234
—
—
—
17
27
260
3105
17
70
177
2373
Oxygen saturation in Arterial blood
2708-6 [3016502]
7.7e-01
1.9e+00
—
—
—
1.9e+00
1.2e+00
cases:4.89%
controls:2.33%
cases:5.50%
controls:0.83%
—
—
—
—
—
—
cases:5.42%
controls:0.83%
cases:8.25%
controls:2.58%
16
76
311
3187
18
27
309
3236
—
—
—
15
26
262
3106
16
63
178
2380
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
1.1e+00
2.5e+00
—
—
—
9.1e-01
1.5e+00
cases:5.20%
controls:1.81%
cases:5.20%
controls:0.46%
—
—
—
—
—
—
cases:1.81%
controls:0.73%
cases:8.25%
controls:1.96%
17
59
310
3204
17
15
310
3248
—
—
—
5
23
272
3109
16
48
178
2395
cycloSPORINE [Mass/volume] in Blood
3520-4 [3010375]
—
2.6e+00
—
—
1.0e+50
2.4e+00
—
—
—
cases:2.45%
controls:0.18%
—
—
—
—
cases:1.61%
controls:0.00%
cases:2.17%
controls:0.19%
—
—
—
8
6
319
3257
—
—
5
0
305
3256
6
6
271
3126
—
Immunization
WW200 [2001310599]
2.1e+00
—
—
—
—
—
3.0e+00
cases:2.14%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
cases:4.64%
controls:0.25%
7
9
320
3254
—
—
—
—
—
9
6
185
2437
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
2.2e-01
1.1e+00
2.0e+00
—
2.3e+00
1.6e+00
7.0e-01
cases:9.17%
controls:7.51%
cases:7.95%
controls:2.73%
cases:1.53%
controls:0.21%
—
—
cases:2.90%
controls:0.31%
cases:9.39%
controls:2.01%
cases:14.43%
controls:7.70%
30
245
297
3018
26
89
301
3174
5
7
322
3256
—
9
10
301
3246
26
63
251
3069
28
188
166
2255
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
6.0e-01
9.4e-01
1.9e+00
—
2.1e+00
6.5e-01
4.5e-01
cases:8.26%
controls:4.72%
cases:6.42%
controls:2.60%
cases:3.06%
controls:0.46%
—
—
cases:3.55%
controls:0.43%
cases:6.86%
controls:3.70%
cases:12.89%
controls:8.60%
27
154
300
3109
21
85
306
3178
10
15
317
3248
—
11
14
299
3242
19
116
258
3016
25
210
169
2233
Status asthmaticus
J46 [45591560]
2.2e+00
—
1.0e+50
1.0e+50
—
—
2.7e+00
cases:2.75%
controls:0.31%
—
—
cases:1.83%
controls:0.00%
cases:1.53%
controls:0.00%
—
—
—
—
cases:3.09%
controls:0.20%
9
10
318
3253
—
6
0
321
3263
5
0
322
3263
—
—
6
5
188
2438
ciclesonide; nasal
R01AD13 [43534836]
1.6e+00
1.6e+00
—
—
—
1.7e+00
1.1e+00
cases:6.12%
controls:1.32%
cases:3.98%
controls:0.83%
—
—
—
—
—
—
cases:5.05%
controls:0.93%
cases:5.15%
controls:1.72%
20
43
307
3220
13
27
314
3236
—
—
—
14
29
263
3103
10
42
184
2401

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
109
21
77.36
197.58
3.8
1.3
8.77
0.09
u/ml
5.73
93
13
106
53
29.11
144.82
6.2
2.4
—
—
—
0
0
203
370
12.83
124.87
5.7
1.4
—
—
—
0
0
114
9
193.13
114.82
3.0
1.7
—
—
—
0
0
127
178
11.03
93.24
4.9
1.3
1233.23
296.55
u/ml
2.19
121
165
124
248
7.44
64.69
5.4
2.3
9.53
10.94
g/l
2.47
113
228
55
50
13.02
53.38
6.0
2.8
—
—
—
0
0
151
442
5.49
50.78
3.6
2.0
—
—
—
0
0
154
506
4.86
43.87
13.1
3.4
0.80
0.83
mmol/l
2.25
149
483
40
30
15.05
43.28
1.4
1.3
2.69
2.71
g/l
0.02
23
25
40
30
15.05
43.28
1.4
1.3
0.39
0.41
g/l
0.06
24
25
123
351
5.01
41.49
2.9
1.6
—
—
—
0
0
219
974
4.78
41.14
23.8
6.5
—
—
—
0
0
39
32
13.70
39.99
1.4
1.3
—
—
—
0
0
46
52
10.13
38.12
1.5
1.9
0.80
1.03
g/l
0.33
30
44
85
199
5.42
35.79
2.8
1.6
1.20
1.34
g/l
0.20
78
180
43
49
9.95
35.35
3.6
1.7
—
—
—
0
0
43
49
9.95
35.35
3.6
1.7
—
—
—
0
0
43
49
9.95
35.35
3.6
1.7
—
—
—
0
0
43
49
9.95
35.35
3.6
1.7
—
—
—
0
0
192
896
3.77
30.85
11.0
4.6
—
—
—
0
0
68
153
5.35
29.63
1.8
2.2
1.79
1.46
g/l
1.44
56
137
123
438
3.90
29.53
1.8
1.8
—
—
—
0
0
257
1491
4.38
29.01
23.0
6.4
0.67
0.60
e9/l
4.74
241
1277
257
1496
4.35
28.74
22.9
6.4
0.05
0.04
e9/l
1.56
242
1282
32
32
10.98
28.72
1.4
1.3
—
—
—
0
0
257
1518
4.24
27.59
23.2
6.4
1.72
1.87
e9/l
1.25
244
1341
32
34
10.32
27.51
3.0
2.5
10.76
23.72
iu/ml
—
10
5
258
1544
4.18
26.78
25.5
6.6
0.23
0.20
e9/l
1.27
245
1351
57
121
5.49
26.38
1.6
1.4
—
—
—
0
0
108
401
3.53
23.65
14.2
6.3
1.05
1.04
mmol/l
0.21
102
380
260
1663
3.75
22.15
33.4
10.6
4.59
4.16
e9/l
2.05
249
1460
42
82
5.73
21.14
1.5
1.3
—
—
—
0
0
224
1348
3.10
20.36
14.0
6.5
1.21
1.21
mmol/l
0.42
218
1245
25
7
38.48
20.14
7.5
1.4
—
—
—
0
0
82
280
3.57
20.13
11.1
4.4
0.91
0.87
%
0.06
54
106
79
266
3.60
19.79
10.8
4.4
0.79
0.56
%
0.60
53
96
35
61
6.31
19.75
2.1
1.4
—
—
—
0
0
216
1292
2.98
19.51
11.4
5.3
32.71
35.44
g/l
7.86
211
1219
33
56
6.44
19.10
2.1
1.4
137.58
159.38
au/ml
0.39
12
13
29
43
7.30
19.01
11.3
3.7
—
—
—
0
0
235
1488
3.06
18.81
18.2
7.5
1.21
1.21
mmol/l
0.29
214
1291
91
365
3.07
16.91
9.8
7.3
1.57
0.71
mmol/l
1.15
78
305
91
367
3.05
16.73
9.8
7.3
7.42
7.41
ph
0.48
56
216
73
260
3.33
16.54
11.7
4.5
0.11
0.15
%
0.23
47
85
94
399
2.90
15.66
1.6
1.3
473.04
415.60
titre
0.15
23
100
162
906
2.56
15.53
9.1
4.6
7.40
7.40
ph
0.10
123
642
143
767
2.54
14.82
2.9
2.2
3.16
3.06
mg/l
0.17
128
663
42
111
4.19
14.66
5.1
2.0
22.52
21.45
s
0.15
42
105
20
9
23.56
14.40
1.1
1.0
—
—
—
0
0
70
271
3.01
13.60
12.6
4.9
0.14
0.19
%
0.16
44
84
19
9
22.31
13.49
1.3
1.2
—
—
—
0
0
68
262
3.01
13.31
11.9
8.6
—
—
—
0
0
20
12
17.65
13.15
1.7
1.2
—
—
—
0
0
55
189
3.30
13.04
4.2
4.1
—
—
—
0
0
115
589
2.47
12.81
2.3
1.4
2.24
2.53
g/l
1.01
92
360
33
81
4.42
12.63
1.7
2.4
119.11
126.66
g/l
0.62
18
62
60
225
3.04
12.26
8.0
3.7
7.43
7.42
ph
0.88
53
185
16
6
27.92
12.16
3.8
1.8
34.38
29.17
%
—
16
6
17
9
19.84
11.71
3.8
3.2
—
—
—
0
0
28
64
4.69
11.69
1.6
1.1
294.43
301.61
u/ml
0.03
14
31
23
26
9.43
11.46
1.2
1.2
—
—
—
0
0
96
476
2.44
11.28
6.1
3.3
1.06
1.69
e6/l
0.76
62
246
16
8
20.94
11.24
2.5
1.1
—
—
—
0
0
141
827
2.24
11.18
6.2
3.4
0.40
0.44
e6/l
0.06
119
608
50
178
3.14
11.13
5.1
3.9
24.74
24.22
mmol/l
0.42
50
178
144
857
2.22
10.96
22.1
6.5
—
—
—
0
0
212
1475
2.24
10.85
16.7
14.1
1.21
1.26
inr
0.83
185
1227
120
667
2.26
10.76
3.2
1.7
2.33
1.53
mg/l
0.49
107
536
70
305
2.65
10.74
6.5
3.8
2.54
1.79
mmol/l
0.69
62
257
193
1298
2.19
10.70
32.3
12.1
0.00
0.00
e9/l
0.08
165
1064
55
212
2.92
10.64
1.6
1.5
—
—
—
0
0
238
1761
2.29
10.12
11.9
4.9
6.55
6.74
mmol/l
0.83
230
1681
56
224
2.81
10.11
2.4
2.5
—
—
—
0
0
67
295
2.60
10.03
2.6
1.5
—
—
—
0
0
70
315
2.56
10.02
5.4
2.9
60.98
69.96
e9/l
1.32
51
234
21
26
8.55
9.99
1.6
1.2
—
—
—
0
0
132
781
2.16
9.99
5.9
3.3
—
0.00
estimate
—
0
6
14
7
20.81
9.88
5.4
3.3
—
—
—
0
0
99
524
2.28
9.86
4.1
2.7
10.31
13.08
umol/l
3.66
93
488
21
44
5.03
9.68
1.8
1.3
—
—
—
0
0
94
492
2.28
9.58
3.8
2.7
2.14
2.27
g/l
1.43
88
454
276
2202
2.62
9.51
30.7
9.1
86.70
80.69
u/l
1.30
271
2092
19
37
5.39
9.48
1.6
1.2
—
—
—
0
0
158
1018
2.07
9.40
7.0
3.6
2.31
2.35
mmol/l
2.73
150
914
69
318
2.48
9.35
6.6
3.8
7.37
7.38
ph
1.63
49
187
90
467
2.28
9.33
3.9
2.6
17.83
23.18
%
3.48
84
438
26
68
4.07
9.15
3.0
2.6
57.00
60.32
%
0.50
26
68
28
78
3.83
9.05
8.1
3.4
2.65
2.19
index
0.16
20
48
60
264
2.56
8.94
1.9
1.4
—
—
—
0
0
77
381
2.34
8.88
5.1
2.9
5.03
4.97
e9/l
0.03
63
332
20
29
7.27
8.69
1.7
2.8
45.50
40.60
%
—
8
15
241
1849
2.15
8.54
7.4
4.7
12.13
145.10
e6/l
—
8
41
178
1233
1.97
8.30
3.6
2.5
78.40
76.89
nmol/l
0.26
164
1098
151
992
1.97
8.19
6.6
3.4
54.05
121.77
e6/l
0.44
128
779
20
47
4.47
8.06
3.4
2.6
5.47
4.65
e9/l
0.48
20
47
31
103
3.22
7.69
1.9
3.7
1.79
2.61
ratio
0.42
18
63
147
972
1.93
7.69
8.9
2.6
—
—
—
0
0
64
312
2.31
7.56
11.3
7.8
117.97
121.53
g/l
0.77
64
306
66
327
2.28
7.51
2.0
1.6
—
—
—
0
0
40
158
2.75
7.34
10.2
3.9
—
—
—
0
0
43
177
2.65
7.29
14.1
8.4
15.56
15.85
%
0.30
43
170
161
1112
1.88
7.25
7.8
4.1
15.39
84.80
e6/l
3.52
132
810
100
593
1.99
7.10
4.2
2.9
552.99
547.66
mosm/kgh2o
0.09
94
522
32
114
3.00
7.07
1.9
4.2
53.56
57.05
mg/l
0.09
27
100
32
114
3.00
7.07
1.9
4.2
40.35
51.83
mg/l
0.28
26
101
11
8
14.17
6.94
1.9
1.6
—
—
—
0
0
25
78
3.39
6.85
1.6
1.6
—
—
—
0
0
13
14
9.62
6.85
2.8
1.3
41.85
60.75
ug/l
0.70
13
14
178
1286
1.84
6.80
4.8
3.0
375.24
146.35
ug/l
1.12
172
1192
10
6
17.14
6.78
1.1
1.0
—
—
—
0
0
11
9
12.59
6.63
1.1
1.0
—
—
—
0
0
18
46
4.08
6.53
1.4
1.2
1.91
3.79
u/ml
0.77
11
19
122
792
1.86
6.51
8.2
3.1
337.39
357.02
umol/l
1.30
112
701
184
1355
1.82
6.49
7.4
2.9
—
—
estimate
—
0
0
155
1084
1.82
6.49
2.7
2.2
—
—
—
0
0
56
276
2.24
6.41
3.1
2.7
32.65
37.04
u/l
0.37
49
231
18
36
5.23
6.28
1.2
1.3
—
—
—
0
0
41
179
2.48
6.16
1.7
1.7
—
—
—
0
0
70
384
2.05
6.08
2.0
1.6
—
—
—
0
0
12
15
8.26
5.89
2.0
2.2
2162.83
1077.07
u/ml
0.42
12
15
22
70
3.30
5.86
1.9
5.0
—
—
—
0
0
238
1943
1.83
5.49
7.4
4.5
—
2.43
—
0
6
83
503
1.87
5.35
1.7
1.7
989.50
1250.11
nmol/l
2.15
65
378
21
69
3.18
5.32
1.6
1.2
—
—
—
0
0
21
69
3.18
5.32
4.3
2.9
—
—
—
0
0
15
30
5.19
5.32
1.4
1.5
—
—
—
0
0
103
669
1.79
5.30
14.3
5.1
—
—
—
0
0
163
1219
1.67
4.96
5.2
4.0
29.83
38.91
ng/l
0.68
125
923
41
198
2.22
4.91
8.0
6.2
24.93
24.19
mmol/l
0.65
41
188
14
30
4.83
4.74
1.4
1.0
—
—
—
0
0
173
1326
1.65
4.69
2.7
2.1
96.11
96.11
pmol/l
0.00
117
697
16
48
3.45
4.67
2.3
1.5
—
—
—
0
0
120
843
1.67
4.55
3.5
3.1
—
—
—
0
0
14
32
4.52
4.49
1.0
1.2
—
—
—
0
0
93
612
1.73
4.48
4.9
3.9
432.36
391.50
ng/l
0.08
80
498
14
33
4.38
4.37
1.4
1.6
—
—
—
0
0
22
84
2.74
4.33
1.2
1.2
—
83.75
—
0
8
129
936
1.62
4.24
2.2
1.7
17.34
20.18
nmol/l
1.97
122
782
11
21
5.38
4.18
12.0
2.6
0.36
0.86
index
1.70
11
21
20
74
2.81
4.17
1.3
1.6
287.29
280.11
ug/g
0.05
14
48
8
10
8.17
4.08
11.6
4.5
45.13
50.10
%
—
8
10
22
87
2.64
4.06
7.7
6.0
1.17
1.32
mmol/l
0.37
22
78
244
2725
0.59
3.98
5.3
5.3
1.41
1.42
mmol/l
0.17
230
2511
98
674
1.65
3.94
4.6
3.8
—
0.25
—
0
8
48
268
1.93
3.92
2.4
2.4
14.32
9.07
ug/l
0.71
42
238
7
8
8.91
3.79
1.4
1.5
—
—
—
0
0
29
136
2.24
3.74
1.8
1.3
—
—
—
0
0
53
312
1.83
3.68
2.0
2.5
288.95
113.13
ug/g
0.95
41
246
252
2780
0.59
3.65
5.9
6.1
2.57
2.63
mmol/l
0.51
234
2568
25
112
2.33
3.58
1.9
2.3
3.05
5.31
iu/ml
—
6
33
13
37
3.62
3.44
2.1
2.2
—
—
—
0
0
11
27
4.18
3.42
1.6
3.6
1110.36
937.48
mg
0.13
11
27
155
1218
1.52
3.40
4.4
3.6
6.23
6.19
ph
0.17
87
706
248
2732
0.62
3.25
5.3
5.4
4.48
4.51
mmol/l
0.19
233
2529
185
1520
1.50
3.21
5.1
3.8
0.00
0.00
estimate
-0.00
36
306
123
929
1.52
3.21
4.3
2.2
156.12
296.12
u/l
0.86
116
883
12
35
3.52
3.14
1.7
1.9
—
—
—
0
0
33
176
1.97
3.09
2.2
2.6
—
12.95
—
0
17
9
21
4.38
3.01
2.3
1.3
—
—
—
0
0
185
1534
1.47
2.98
5.2
3.9
0.00
0.00
estimate
-0.00
36
314
43
255
1.79
2.93
3.1
2.2
0.00
0.00
estimate
—
6
54
231
2009
1.51
2.88
7.5
4.4
—
0.14
—
0
7
6
9
6.76
2.88
1.2
1.0
1036.00
1424.00
miu/ml
—
6
9
6
9
6.76
2.88
1.2
1.0
—
—
—
0
0
28
146
2.00
2.80
7.8
4.5
1.70
1.57
%
0.37
28
136
185
1548
1.45
2.76
5.3
3.9
0.00
0.01
estimate
0.50
34
295
7
14
5.08
2.74
1.0
1.1
—
—
—
0
0
26
133
2.04
2.74
8.0
4.7
0.93
0.86
%
0.56
26
123
27
141
2.00
2.69
2.7
2.4
—
—
—
0
0
81
1082
0.67
2.57
3.5
3.3
—
—
—
0
0
59
398
1.59
2.50
1.6
1.3
—
—
—
0
0
12
45
2.73
2.48
1.3
1.1
—
—
—
0
0
11
38
2.96
2.44
2.1
1.0
—
—
—
0
0
11
38
2.96
2.44
2.1
1.0
—
—
—
0
0
126
1002
1.42
2.39
5.0
3.3
1402.78
1315.32
ng/l
0.11
120
852
11
39
2.88
2.36
2.4
2.4
-0.64
0.80
mmol/l
0.83
11
39
214
1869
1.42
2.34
7.4
3.6
68.28
52.54
u/l
1.20
207
1757
51
338
1.60
2.33
4.1
4.6
3.92
49.22
ug/l
1.19
42
284
6
13
4.68
2.28
1.2
1.0
—
—
—
0
0
5
10
5.06
2.08
2.0
3.6
0.61
0.59
mmol/l
—
5
10
244
2644
0.70
2.07
6.5
6.8
40.31
39.62
mmol/mol
0.54
231
2479
11
45
2.49
1.95
4.5
2.4
30.64
32.93
pg
0.94
11
45
5
11
4.60
1.95
1.2
1.2
30.60
27.55
s
—
5
11
14
65
2.21
1.91
7.2
5.6
104.36
105.39
mmol/l
0.54
14
59
14
65
2.21
1.91
7.2
5.6
11.64
11.47
mmol/l
0.07
14
59
43
288
1.57
1.89
3.9
2.6
0.17
0.21
e6/l
0.16
43
278
9
34
2.69
1.88
1.7
1.2
—
—
—
0
0
8
28
2.90
1.87
1.6
1.9
7.74
10.84
%
—
8
28
99
785
1.37
1.84
1.8
1.4
—
—
—
0
0
8
30
2.71
1.73
2.6
1.6
—
—
—
0
0
5
13
3.89
1.72
1.4
1.1
—
—
—
0
0
10
42
2.42
1.63
1.1
1.1
—
12.54
—
0
12
14
70
2.04
1.61
1.4
1.2
—
—
—
0
0
243
2605
0.74
1.56
4.8
4.5
1.31
1.28
mmol/l
0.27
231
2390
8
33
2.46
1.54
1.9
3.1
—
—
—
0
0
289
2735
1.49
1.51
65.4
17.3
30.79
24.98
mg/l
2.47
274
2277
46
330
1.46
1.50
2.2
2.5
14.48
13.35
nmol/l
0.30
40
298
66
506
1.38
1.49
1.4
1.3
26.77
34.99
iu/ml
0.29
17
170
5
16
3.16
1.44
1.0
1.1
132.00
132.38
nmol/l
—
5
16
6
22
2.76
1.44
1.0
1.4
—
—
—
0
0
79
627
1.34
1.44
1.7
1.8
474.72
442.88
pmol/l
0.34
71
527
27
175
1.59
1.39
5.2
2.6
0.77
0.64
%
0.38
27
175
7
146
0.47
1.35
1.0
1.1
—
—
—
0
0
6
24
2.53
1.31
1.2
1.0
—
—
—
0
0
8
34
2.39
1.30
1.0
1.3
—
—
—
0
0
226
2077
1.29
1.29
4.2
4.0
14.93
14.89
pmol/l
0.08
214
1878
45
340
1.38
1.13
1.3
1.4
—
—
—
0
0
50
386
1.35
1.10
1.3
1.3
—
—
—
0
0
15
89
1.72
1.09
1.2
1.3
33.79
26.46
iu/l
—
9
77
5
21
2.40
1.09
4.8
2.3
—
—
—
0
0
10
53
1.91
1.02
1.3
1.4
—
—
—
0
0
80
668
1.26
1.00
4.6
4.1
1.02
1.02
kg/l
0.84
62
445
20
137
1.49
0.86
2.6
2.7
—
—
—
0
0
8
46
1.76
0.83
3.0
2.1
10.77
10.65
mmol/l
—
8
46
0
26
0.00
0.78
0.0
1.0
—
260.24
—
0
17
257
2674
0.82
0.74
5.8
5.4
5.91
6.03
mmol/l
0.70
246
2453
10
60
1.69
0.73
2.1
1.8
2.52
2.88
iu/l
—
5
25
5
28
1.80
0.66
2.4
4.0
7.70
8.67
mmol/l
—
5
28
29
226
1.31
0.64
4.2
3.6
—
—
—
0
0
109
1203
0.86
0.62
2.2
2.0
1.28
1.35
mmol/l
0.61
91
997
0
20
0.00
0.60
0.0
1.7
—
1.42
—
0
14
0
21
0.00
0.60
0.0
1.7
—
—
—
0
0
55
468
1.21
0.60
1.3
1.3
3.17
13.15
u/ml
1.78
20
187
0
23
0.00
0.58
0.0
1.9
—
—
—
0
0
95
851
1.16
0.58
5.3
4.0
0.00
0.01
estimate
0.50
34
287
5
88
0.56
0.57
1.0
1.2
—
—
—
0
0
6
37
1.63
0.56
1.7
1.9
88.13
90.22
%
—
6
37
6
39
1.55
0.53
1.0
1.3
—
—
—
0
0
7
46
1.53
0.48
2.4
7.1
6.47
7.28
mmol/l
—
7
37
127
1181
1.12
0.44
4.5
3.7
0.00
0.02
estimate
0.69
30
266
9
131
0.68
0.44
1.6
1.8
42.67
39.66
nmol/l
—
9
124
8
58
1.39
0.42
1.1
2.8
6.68
9.49
pmol/l
—
8
58
0
15
0.00
0.41
0.0
15.0
—
902.73
—
0
15
26
214
1.23
0.41
1.2
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
3.7
—
34.53
—
0
12
14
107
1.32
0.38
2.4
3.6
221.00
246.39
mg/l
—
8
41
5
37
1.36
0.37
8.8
3.4
5.80
3.24
nmol/l
—
5
37
70
636
1.13
0.36
1.3
1.2
0.88
1.38
u/ml
0.63
22
176
113
1061
1.10
0.32
4.6
3.4
7.05
8.07
mmol/l
1.75
104
882
111
1042
1.10
0.32
5.2
4.2
17.37
7.66
mg/mmol
1.20
79
667
5
72
0.69
0.26
1.8
1.5
—
—
—
0
0
9
77
1.17
0.24
1.2
1.4
—
270.91
—
0
35
6
82
0.73
0.24
2.0
1.5
—
—
—
0
0
15
124
1.22
0.24
3.8
1.9
—
—
—
0
0
108
1026
1.08
0.24
4.4
3.5
79.96
50.35
mg/l
0.66
77
690
7
93
0.75
0.22
1.3
1.1
1.84
1.54
g/l
—
7
93
5
42
1.19
0.21
4.8
3.2
110.20
105.21
mmol/l
—
5
42
5
42
1.19
0.21
4.8
3.2
4.06
4.03
mmol/l
—
5
42
5
42
1.19
0.21
4.8
3.2
1.23
1.18
mmol/l
—
5
42
0
14
0.00
0.20
0.0
10.9
—
0.66
—
0
14
6
51
1.18
0.19
1.3
1.1
—
—
—
0
0
20
175
1.15
0.19
1.1
1.3
—
—
—
0
0
91
869
1.07
0.17
4.3
3.2
0.00
0.00
estimate
0.50
31
247
6
78
0.76
0.15
1.0
1.6
—
—
—
0
0
6
79
0.76
0.15
2.0
1.5
—
—
—
0
0
6
80
0.75
0.15
2.2
1.5
—
—
—
0
0
6
80
0.75
0.15
2.0
1.5
—
—
—
0
0
8
96
0.83
0.14
1.5
1.2
0.83
0.90
g/l
—
8
96
254
2511
1.05
0.11
5.3
5.0
1.86
1.99
mu/l
1.13
238
2296
284
2816
1.06
0.11
41.1
15.4
—
—
—
0
0
9
87
1.04
0.07
1.1
1.1
—
—
—
0
0
10
89
1.13
0.07
1.2
1.2
14.24
8.08
u/l
—
5
69
8
91
0.88
0.07
13.3
13.5
—
—
—
0
0
14
129
1.09
0.05
1.1
1.3
—
—
—
0
0
14
134
1.05
0.00
1.0
1.5
0.18
0.35
mg/l
—
7
56
80
806
0.99
0.00
3.3
3.3
0.61
0.80
ug/l
2.07
58
533
22
218
1.01
0.00
1.2
1.4
—
—
—
0
0
10
95
1.05
0.00
1.6
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
17.30
—
0
6
0
6
0.00
0.00
0.0
1.7
—
59.00
—
0
6
0
6
0.00
0.00
0.0
1.2
—
1.19
—
0
6
0
5
0.00
-0.00
0.0
6.4
—
6.33
—
0
5
6
68
0.88
-0.00
8.8
4.4
30.17
29.12
mg/l
—
6
51
6
64
0.94
-0.00
1.2
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
0.00
—
0
9
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
2664.43
—
0
7
8
80
1.00
-0.00
7.4
4.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
20.20
—
0
5
134
1340
1.00
-0.00
5.2
5.7
1.86
2.52
ug/l
1.26
119
1205
0
7
0.00
-0.00
0.0
4.6
—
24.07
—
0
7

Mortality – FinRegistry

↥

Association

Association between endpoint AB1_ASPERGILLOSIS and mortality.

Females

Parameter HR [95% CI] p-value
AB1_ASPERGILLOSIS 4.089 [3.03, 5.52] < 0.001
Birth year 0.994 [0.99, 1.0] 0.199

During the follow-up period (1.1.1998 — 31.12.2019), 157 out of 432 females with AB1_ASPERGILLOSIS died.

Males

Parameter HR [95% CI] p-value
AB1_ASPERGILLOSIS 5.317 [4.05, 6.99] < 0.001
Birth year 0.988 [0.98, 1.0] 0.016

During the follow-up period (1.1.1998 — 31.12.2019), 377 out of 732 males with AB1_ASPERGILLOSIS died.

Mortality risk

Mortality risk for people of age

years, who have AB1_ASPERGILLOSIS.

N-year risk Females Males
1 0.413% 0.945%
5 2.448% 6.264%
10 6.095% 14.861%
15 11.683% 27.194%
20 19.595% 41.719%

Relationships between endpoints

↥

Index endpoint: AB1_ASPERGILLOSIS – Aspergillosis

GWS hits: 1

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data